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ABSTRACT
THE ROLE OF INTERLEUKIN-12 AND EXOSOMES IN THE DYNAMIC
INTERPLAY OF CANCER AND THE IMMUNE SYSTEM
CHRISTINA NICOLE “NIKKI” BYRNE-HOFFMAN

Melanoma and breast cancers account for a large number of cancer diagnoses and
deaths, with 1 in 28 and 1 in 8 developing melanoma or breast cancer, respectively, in their
lifetime. T Lymphocytes play a pivotal role in the immune system response to cancers and
are known to evade the immune system by a variety of mechanisms, including modulation
of cytokine function. A cytokine important for the function of T lymphocytes, Interleukin-12,
and modulation of its Janus Kinase and activators of transcription (JAK-STAT) signaling
pathway, plays a role in the immune response to tumors, especially melanoma. We
examined the role of interleukin-12 receptor beta 2 as a possible target of immune system
inhibition by melanoma via a cytokine sink and initiation of alternative signaling pathways to
produce cell survival in melanoma, even when challenged with the cytotoxic stressor and
chemotherapy drug imatinib. Additionally, exosomes, nano-sized vesicles containing
immune system-inhibiting proteins and nucleic acids, have also been described as a
potential mechanism of evasion. We investigated the proteomic profiles of exosomes in
human breast cancers, which informed upon studies examining the nucleic acid payloads
in murine melanomas against a murine cytotoxic T lymphocyte model, CTLL2 cells. We
have examined the microRNA contents of exosomes from a murine B16F0 melanoma line
and determined possible target cell alterations in mitochondrial respiration, DNA
modification, and targeting of the Notch pathway. We concluded tumor-derived exosomes
may affect the overall function of immune cells like cytotoxic T lymphocytes, and specific
microRNAs and protein products contained within them may alter cell energetics and certain
transcription and translation products to promote the proliferation and immune evasion
abilities of melanoma, breast, and other cancers.
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INTRODUCTION TO THE DISSERTATION

I.1. MOTIVATION
It is well known tumors persist in part due to the inability of the immune system to
detect and eliminate cells which harbor somatic mutations (Marr 2012). Within a particular
cancer, how a certain somatic mutation contributes to malignant cell survival, and how
cancer and immune cell-to-cell communication affects the ability of the immune system to
rid the body of disease, is largely unknown. This knowledge gap makes it more difficult to
develop effective immunotherapeutics for the treatment of cancer and determine how they
may function in typical patient populations. Filling this gap may provide insight to how cancer
could be prevented or treated by using models which mimic the tumor microenvironment
and using these pre-clinical models to rationally design therapies for specific patient groups
(Hartman 2013).
Our long-range goal is to understand how cancer-induced changes in the tumor
microenvironment affect cytokine signaling and immune function, and therefore the
progression of cancer, in order to develop preventative and therapeutic strategies for this
disorder. The objective of these studies is to characterize the mechanism of action of tumormediated immune suppression and identify the essential classical and noncanonical
pathways they mediate. The central hypothesis of the dissertation is that malignant
melanocytes utilize extracellular miRNA, mRNA, and proteins via exosomes and alterations
of various intra- and intercellular pathways to inhibit cytotoxic T lymphocyte and T helper
cell fate and effector function through the interleukin-12 signaling axis and modification of
other cellular pathways.

This hypothesis is driven by preliminary and published data

collected by our laboratory and others. The rationale for this dissertation research is, that
once potential mechanisms are identified, these mechanisms will provide foci for examining
the effects of immune function on the behavior of malignant melanocytes and suggest
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targets for developing pharmacological interventions for the treatment of melanoma, breast
malignancies, and other cancers.

I.2 STATE OF RESEARCH
I.2.1. Significance
The American Cancer Society estimates in United States during the year 2018, over
1.7 million new cases of cancer will have been diagnosed, and over 268,000 and 87,000
of new cancer cases will be breast cancer and melanoma, respectively (Siegel et al. CA: A
Cancer Journal for Clinicians ACS Cancer Statistics, 2018). It is estimated that 1 in 8 men
and women will develop breast cancer and 1 in 28 will develop melanoma in their lifetime,
and over 50,700 individuals will die due to complications of these diseases. Cancer
incidence and mortality also significantly increase with age (National Cancer Institute,
SEER 1975-2008) and are attributed to sequential acquisitions of somatic mutations
through DNA damage and repair. These mutations alter the behavior of normal cells and
enable them with a number of “hallmarks” of malignant cells (Hanahan 2000).

The

emerging hallmark of “Evading immune destruction” is now being investigated more closely
to attempt to aid in the search for better cancer therapies (Hanahan 2010).
Immunotherapy is a rapidly developing method of treatment for certain cancers,
such as melanoma, with recent focus on regulation of T cell activation in drugs such as
ipilimumab (Hodi 2010). It has been shown that cytotoxic T lymphocytes (CTLs) and their
perforin-dependent cytotoxic actions are necessary components for

immunotherapy

response in ipilimumab (van Elsas 2001). CTLs are one of the immune system’s main
defense against developing a malignancy. Activation of these cells leads to an attempt to
eradicate tumor cells from the body, utilizing cell-mediated removal and enzyme-mediated
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degradation of tumor products (Franciszkeiwicz 2012). Tumors may overcome this system
by manipulating cytokine pathways, upon which immune cells rely for proliferation and
activation, or by secreting exosomes, a mammalian cell-produced nano-sized vesicle of
approximately 30-120nm in size, to affect the function of immune system cells, such as CTLs
(Raposo 2013).
Interleukins and other cytokines have had a history of use in the treatment of cancer,
as a method of increasing immune system reactivity to cause elimination of the tumors. For
instance, interleukin-12 (IL-12) can boost natural killer and CTL activity, while also causing
polarization of T helper cells towards a Th1 phenotype. IL-12 has also exhibited prevention
of angiogenesis (Carreno 2013, Golab 1999, Athie-Morales 2004). While toxicity limits
systemic IL-12 therapies, local delivery of IL-12 to the tumor microenvironment has been
shown to promote tumor regression (Chinnasamy 2012). IL-12 signals via a canonical
Janus-Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) signaling
pathway. The IL-12 receptor, composed of a β1 and β2 subunit, lacks intrinsic enzymatic
activity and forms a complex with two JAKs, JAK2 and Tyk2 (Figure I.1). After binding of IL12 to the receptor, autophosphorylation of the receptor results in binding and activation of
STATs, which then form a dimeric transcription factor (Murray 2007, Watford 2004, Zhu
2010). While the canonical IL-12 signaling cascade is rather straightforward, there are data
to support that the IL-12 receptor contains additional binding motifs which may lead to the
activation of non-canonical signaling elements (Duitman 2011, Lin 2007, Zhang 2008).
Additionally, our laboratory has found B16 melanoma cells overexpress the IL12Rβ2
subunit, providing a link as to how this cancer may be able to undermine the immune
system. One of the objectives of these studies is to elucidate how these non-canonical
signaling elements contribute to immune cell survival and may be subverted in cancer.
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Figure I.1. Interleukin-12 Receptor Dimer with Binding Sites. IL12RB1 (CD212) binds
the p40 subunit of IL12p70, while IL12RB2 binds the p35 subunit of IL12p70. The
TYK2 kinase binds to IL12RB1 intracellularly, while JAK2 binds IL12B2. STAT4 also
directly associates with the IL12RB2 subunit through SH2 domains.

Exosomes are used by cells to transport information in the form of proteins and
nucleic acids, such as microRNA (miRNA) (Vlassov 2012). Quite often, the expression of
certain miRNAs and their relative amounts differ between the parent cell and the cell-derived
exosomes, which suggests miRNAs are selectively packaged into exosomes (Figure I.2).
This extracellular transport by exosomes of mRNAs and microRNAs may then be able to
control microenvironment processes, such as immune function initiation, and influence
target cell function by inhibiting or stimulating certain pathways within the target cell and its
surroundings by influencing protein translation (Raposo 2013, Thery 2002, Zomer 2010).
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Figure I.2.

Density of microRNAs in Parental Cells versus Exosomes.

Approximately 30% of microRNAs were shared between parental B16F0 cells and
their exosome fractions. A higher fraction of unique miRNAs were found in the
exosome fraction at 40%, while parental cells showed only 30% of their miRNAs as
unique to parental cells.

Some of the most notable exosomes are those which are produced by cancer cells.
Because exosomes can be a “fingerprint” of the cell from which they were derived, they
are being investigated as a biomarker for many diseases, including cancer (Taylor 2008,
Rabinowits 2009). How these exosomes influence cancer progression and metastasis
remains unknown, but miRNA contents of exosomes may alter cancer and immune cell
function within the tumor microenvironment by promoting oncogenesis (Vlassov 2012). In
essence, cancer cells produce intrinsic nanotoxicity within a tumor microenvironment. In
addition, they are of interest in development of nanotherapies, due to their small size, cellto-cell communication through both solubility and direct contact, and distinct effect on
administration, distribution, metabolism, and excretion (Chaput 2005, Kooijmans 2012,
Tan 2010).
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Providing insight to the underlying mechanisms of how immune cells function in
response to the tumor microenvironment is essential for developing effective therapies and
may bring us one step closer to fully understanding these disorders, which is, of yet, still
unattainable. Here, we propose to investigate the possible cytokine sink consequences of
overexpression of the IL12Rβ2 subunit in B16 melanoma cells, whether this observation is
conserved in other cancers, and the evolutionary rationale for why certain cancers, such as
breast cancers and melanoma, produce exosomes. All of these actions may have an effect
on T lymphocyte activity. We believe this mechanism may play a role in the immune evasion
processes of certain cancers, particularly melanoma, which masks its presence and causes
immunosenescence through dampening the immune response of certain active T cell
populations. By this method, cancer may be able to slip under the radar of immune
surveillance and allowed to persist despite activities in which there are innate immune
triggers.

I.2.2. Innovation
Exosomes may provide an ideal model for understanding the function of
endogenous nanoparticles and how they may help us more effective design nanomaterials
to manipulate biological responses for therapeutic aims (Tan 2010), especially
immunotherapeutics. Additionally, this research will help develop fundamental knowledge
of exosomes as a mechanism for cell-to-cell communication (Gutierrez-Vazquez 2012,
Kooijmans 2012). It is known that synthetic nanoparticles may produce nanotoxicity and
have effects on health outcomes, but there is little evidence on ability of endogenous
nanoparticles, such as exosomes and the RNA and protein products contained therein, to
cause disease or effect progression of pathology. It is largely unknown what the effect of
extracellular RNA on cell fate and function may be. We will assess cancer cell exosome
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contents and how their payload may facilitate cancer progression. Additionally, we provide
details on alterations in the IL-12 signaling axis that lead to noncanonical signals, observed
for the first time in melanoma. Comprehending these relatively novel modes of cell-to-cell
communication is important for understanding underlying biological processes of disease
and can provide insight on how to treat many disorders. It is our hope this information about
endogenous nanoparticles can then be used to develop better nanomaterials and to mitigate
nanotoxicity and eradicate disease, and that providing details on how certain cancers are
able to hijack immune cell pathways may lead to new and improved interventions in the
treatment of cancer.

I.2.3. Approach
We leverage methods conventionally used in the analysis of engineered systems,
namely quantitative high-content assays, systems analysis, and model-based inference
which have been described as quantitative systems pharmacology (QSP) (Iyengar 2012,
Finley 2011, Klinke 2010, Klinke 2012). NIH is looking towards QSP approaches to help
improve the translation of basic science discoveries into Federal Drug Administrationapproved drugs (Sorger 2011). To test our central hypothesis, we proposed an
interdisciplinary approach, with involvement of a variety of technological specialties. We
have retained traditional and high content molecular biology techniques such as flow
cytometry and RT-PCR to observe protein expression and JAK-STAT pathway behavior;
key to analyzing the effects of IL-12 signaling on cellular networks. We examined exosome
content for specific RNAs which steadily appear within certain cancer cell type exosomes,
such as those produced by B16 melanoma cells. Given this exosomal payload of RNA,
we then studied the consequences that these RNAs may have on proteins that regulate
anti-tumor immunity to combat cancer development.
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There are several research questions these studies pose. Previous work by our
laboratory has shown co-culture with malignant melanocytes decreases the viability of
immune cells (Kulkarni 2012). However, we wanted to know the mechanisms by which
melanoma and other cancers, such as breast cancer, may be able to exert this effect. Firstly,
are exosomes produced by our cancer cell models? What immune cell pathways do the
products contained in exosomes target? Can cancer cells directly use immune cell signals
for their growth advantage? Are alterations in the IL-12 pathway and is the overexpression
of the IL-12 receptor advantageous for melanoma’s survival, especially under immune cell
attack? These questions are described in the following specific aims. As our focus is on in
vitro studies, how certain miRNAs influence gene expression within target cells and the longterm consequences of the evolutionary adaptation of cancer cells to respond to immune
signals in vivo will be addressed in future studies.

I.3 SPECIFIC AIMS OF THE DISSERTATION

Specific Aim 1. Determine whether cancer cells, such as melanoma and breast
cancers, are able to use signals through the Interleukin-12 signaling axis for their
growth, proliferation, and survival, including under chemotherapy challenge.

Specific Aim 2. Investigate whether cancer cells produce unique forms of cellular
communication through exosomes to inhibit immune cell function.

The conclusions from the first specific aim intend to provide insight to the potential
intrinsic mechanisms for melanoma that inhibits T cell effector function and connects to
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observed cytokine sink activity.

In short, we determined melanoma cells have the

intracellular signaling machinery and are able to utilize immune cell signals through
IL12Rβ2 to promote growth, proliferation, and survival when challenged with imatinib. The
second specific aim demonstrated two points: (1) cancers may alter the selective
landscape and immune response in cancer, and (2) this landscape may be altered by
melanoma and breast cancers we tested through secretome and exosome activity. We
accomplished this by examining the payload of 3 different breast cancer cell lines and a
melanoma line to determine what factors are present in their secretomes that may affect
immune cell function.

Specific Aim 1: Determine whether cancer cells, such as melanoma, are able to use
signals through the Interleukin-12 axis for their growth, proliferation, and survival,
including under chemotherapy challenge.
Experiment 1a. Determine the expression status of IL12R in B16F0 melanoma cells.
Flow cytometry was used to investigate levels of IL-12Rb1 and IL12Rb2. Viability was
measured using a flow cytometric Live/Dead Alexa 405 stain or by fluorescent microscopy
methods with Hoescht 33342 and propidium iodide staining for apoptosis and necrosis.
Experiment 1b. Examine effect of IL-12 stimulation on activation of the IL-12 pathway
and survival signaling pathways. Flow cytometry was used as described in Experiment
1a to observe possible changes in IL-12-induced signaling and cell fate. Cells were treated
with increasing concentrations of IL-12p70 and probed for activation of STAT4, presumably
through IL12R. This method was also used to investigate possible cell survival pathways,
such as those mitigated through activation (phosphorylation) of Akt, when cells are exposed
to this cytokine.
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Experiment 1c. Examine effect of chemotherapy drug imatinib on B16F0 cell viability
and whether IL-12 is able to prevent apoptosis and necrosis. B16F0 cells were cultured
in the presence of imatinib and/or IL-12 to investigate the cell survival effects of IL-12 in a
protocol designed to mimic chemotherapy. A positive control for induction of IL-12 signaling
was administration of IL-12p70 (40, 50, 100, and 200 ng/mL), while imatinib alone (5, 10,
and 20 uM) was used to determine baseline cell death in response to the drug.

Specific Aim 2:

Investigate whether cancer cells, such as melanoma and breast

cancers produce unique forms of cellular communication through exosomes to
inhibit immune cell function.
Experiment 2a. Examine BT474, SKBR3, and 184A1 human breast cancer lines for
evidence of exosomes that may target immune cell function in their secretomes. This
dissertation built on previous data obtained by Yogesh Kularni, a previous student in the
Klinke laboratory. A proteomics workflow using 2D electrophoresis and MALDI-TOF mass
spectrometry was used to examine the 0 and 48 hr secretomes of BT474, SKBR3, and
184A1 cell lines. Proteins of interest were identified using peptide mass fingerprints and
comparing them to protein primary sequence databases. This proteomic data was validated
by western blot for the following proteins: HSPA5, Ezrin, and ILF2. Functional annotation
with GeneMANIA inferred protein-protein interaction networks. Scanning electron micrscopy
was used to examine the presence of exosomes in the seretome samples.
Experiment 2b.

Examine B16F0 melanoma exosome effect on the CTLL2

transcriptome and whether effector function pathways are targeted. Exosomes from
B16F0 melanoma were aseptically isolated according Thery et al. (2006) and co-cultured
with the CTLL2 cell line at a concentration of 1.0 mg/mL. Cells were imaged and after 24
hrs, CTLL2 cells were rinsed with PBS and RNA isolated. Affymetrix was used to analyze
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mRNA and miRNA of the raw B16 exosomes.

RNA-seq was used to analyze the

transcriptome of the CTLL2 cells in response to B16 exosome stimulation. Quantitative
reverse-transcriptase PCR validated the mRNA and miRNA microarray results. Oxygen
consumption rate was used to gauge mitochondrial respiration of CTLL2 cells in response
to B16 exosome treatment. Cytometric Bead Arrays were also used to analyze cytokines
excreted by the CTLL2 cells and an ATPLite assay was used to determine viability. The
transcriptome was analyzed using high-performance computing techniques.

I.4 CHAPTER CITATIONS, SUMMARIES, AND RATIONALE
I.4.1 CHAPTER 1: MELANOMA UTILIZES INTERLEUKIN-12 FOR ITS SURVIVAL IN
RESPONSE TO CHEMOTHERAPY
These studies primarily answered questions related to Specific Aim 1. This chapter
is the text from the article with the following citation:
Byrne-Hoffman CN, Deng W, Wang P, Rojanasakul Y, Klinke DJ II. (Submitted-2018),
Interleukin-12 elicits a non-canonical response in B16 melanoma cells to enhance
survival.

This article is in revisions. At the time of writing this dissertation, additional cell lines
were being tested to satisfy reviewer comments for full acceptance for publication.
Given previous results in our laboratory regarding B16F0 expression of IL12R, we
hypothesized IL-12 will stimulate janus-kinase pathways within the B16 melanoma cell,
similarly to 2D6 murine Th1 clones studied in our laboratory, such as phosphorylation of
STATs. We expected STAT4 serves as the primary intracellular responder to exogenous
IL12p70, given the association of STAT4 with the IL12RB2 subunit and the upregulation
of IL12RB2 in our cell line of interest. Chapter 1 details the molecular alterations we
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observed in the B16F0 melanoma cells that may explain its apparent cytokine sink function
in previous studies. Flow cytometry was used to examine the levels of IL12R in the B16F0
melanoma cells and the effect of IL-12 on B16F0 cells JAK-STAT signaling pathways.
Flow cytometry and luminescence assays were used to determine cell viability of B16F0
cells under chemotherapy challenge with imatinib. Pre-treatment with IL12p70 was used
to simulate local immune cell activity in the tumor microenvironment, and the effects of IL12 pre-treatment on viability, at baseline and with chemotherapy (imatinib), were
assessed.

I.4.2. CHAPTER 2:

BREAST CANCER SECRETOMES CONTAIN EXOSOMES

TARGETING IMMUNE FUNCTION
These studies primarily answered questions related to Specific Aim 2. This chapter
is the text from the article with the following citation:
Klinke, D. J., Kulkarni, Y. M., Wu, Y. and Byrne-Hoffman, C. (2014), Inferring alterations in
cell-to-cell communication in HER2+ breast cancer using secretome profiling of
three cell models. Biotechnol. Bioeng., 111: 1853–1863. doi:10.1002/bit.25238

Supplemental data and information is not included in this dissertation document, but
is available via multiple public access platforms, including PubMed PMC.
We hypothesized BT474, SKBR3, and 1841A secretomes possess protein profiles
that support the presence of exosomes and that these exosomes contain products that
target immune cells.

Chapter 2 details the comparison among the secretomes of two

HER2+ breast cancer lines, BT474 and SKBR3 and an immortalized human mammary
epithelial line 184A1. Proteins involved in antigen-processing and presentation and in
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glycolytic metabolism were found to be enriched in these HER2+ cell lines. Protein-protein
interactions were inferred in the secretome profiles indicated that exosomes promote two
hallmarks of cancer: the evasion of the immune system and the deregulation of cellular
metabolism.

I.4.3. CHAPTER 3: MELANOMA EXOSOMES IMPACT CYTOTOXIC T LYMPHOCYTE
TRANSCRIPTOMES AND MITOCHONDRIAL RESPIRATION
These studies primarily answered questions related to Specific Aim 2. This chapter
is the text from the article with the following citation:
Bland C, Byrne-Hoffman CN, Fernandez A, Rellick SL, Deng W, Klinke DJ II. (in press2018), Exosomes derived from B16F0 melanoma cells alter the transcriptome of
cytotoxic T cells that impacts mitochondrial respiration. FEBS J.

Supplemental data and information is not included in this dissertation document, but
will be available via multiple public access platforms upon full publication by FEBS.
The IL-12 pathway has been shown to effect cell survival pathways in both cancer
and immune cells in various paradigms (Kulkarni 2012, Klinke 2012), and helps to
coordinate the immune response via cell-mediated immunity (Finley 2011). Our laboratory
also observed that B16F0 cells also excrete exosomes that contain miRNAs that target
CTLL2 effector function. Targeting CTL effector function would promote tumor proliferation
and illustrate how cancer cells directly modulate the immune system within the tumor
microenvironment. High throughput biochemical methods, such as cDNA microarray and
RNA sequencing, were used in conjunction with targeted quantitative analysis of certain
RNAs by real-time polymerase chain reaction (PCR) to examine the role these targets
may play in immune subversion by cancer. Correlation between certain CTL cytotoxic
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pathways and IL-12 signaling were observed in previous studies as possible miRNA
candidates for investigation from our microarray results. These miRNAs were upregulated
in the B16 melanoma exosome, indicating a possible targeted pathway for melanoma
survival advantage (Table 1). Validation of additional miRNA candidates and inhibition
studies utilizing flow cytometry and western blot were used to verify effect on cell viability
and protein expression in various biochemical pathways, including IL-12 signaling and
CTL effector function.

Immune
Cell Target

Prf-1
Gzmb

IL-12Rβ2

miRNA
name
miR34c
miR328
miR320
miR378
miR181b
Let-7a
Let-7b
Let-7c
Let-7d
Let-7f

Exosome
Relative
Expression to
Control
6.503
7.83
6.849
9.052
8.749
11.015
12.011
12.077
5.171
2.475

Relative
Difference
(Exosome/B16
cell)
0.460
3.369
-0.953
-0.248
-0.978
-1.054
1.226
-1.5524
0.658
-6.919

mirSVR
score
-0.4261
-0.1939
-0.1337
-0.2225
-0.4657
-1.0741
-1.0741
-1.0741
-1.0741
-1.0766

Table I.1. Possible miRNA candidates for CTLL2 target pathways. mirSVR score
predicts likelihood of target mRNA downregulation.

To answer these questions, B16 melanoma and other cancer cell exosomes were
isolated. After analyzing exosome morphology with scanning electron microscopy (SEM)
and their RNA contents through PCR to determine key pathways, we exposed CTLL2 cells
to exosomes and measured the CTLL2 transcriptomic response. We validated the inferred
functional response, such as a change in mitochondrial respiration, by measuring the
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oxygen consumption rate. Effect of IL-12 on cell viability and proliferation was measured
using flow cytometric, staining, and microscopy-based assays. Changes in how viability and
proliferation is affected by B16 exosomes was also observed. The information in Chapter 3
mostly focuses on the mRNAs and miRNAs that were differentially packaged into B16F0
melanoma exosomes and their effect on CTLL2 cytotoxic T cell transcriptomes. Clusters of
gene expression changes were the direct result of exosome treatment or their payloads,
and these clusters were characterized based on how they may effect the transcriptome of
the CTLL2 cells and therefore their function.

I.4.4. CHAPTER 4: REVIEW OF QUANTITATIVE SYSTEMS PHARMACOLOGY FOR
THE FUTURE DEVELOPMENT OF CANCER IMMUNOTHERAPIES
This chapter is the text from the article with the following citation:
Byrne-Hoffman C and Klinke DJ II. (2015), A quantitative systems pharmacology
perspective on cancer immunology. Processes. 3: 235-256; doi:10.3390/pr3020235
This article will also be indexed on SCIE-Web of Science, but as it is primarily an
engineering journal, it has not yet been made publically available on PubMed. It is
publically accessible through Google Scholar and the Processes website.

In Chapter 4, we review the literature in respect to existing cancer immunotherapies
and the future directions of the pharmacology and pharmaceutical research that should be
the next foci in the fight against cancer. It provides a clinical link to the dissertation studies
and provides rationale for the importance of engaging the immune response when treating
cancer. The basic research that led to those discoveries are described, as well as some of
the pitfalls of current therapies.
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The studies described herein in Chapters 1, 2, and 3, detailing the alterations by
which cancer is able to evade the immune system, illustrate barriers that must be overcome
to expand the efficacy and safety of future cancer immunotherapy pharmaceuticals.
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CHAPTER 1: MELANOMA UTILIZES INTERLEUKIN-12 FOR ITS SURVIVAL IN
RESPONSE TO CHEMOTHERAPY

Within tissues, cells secrete protein signals that are subsequently interpreted by
neighboring cells via intracellular signaling networks to coordinate a cellular response.
However, the oncogenic process of mutation and selection can rewire these signaling
networks to confer a fitness advantage to malignant cells. For instance, the melanoma cell
model (B16F0) creates a cytokine sink for Interleukin-12 (IL-12) to deprive neighboring cells
of this important extracellular signal for sustaining anti-tumor immunity. Alternatively,
oncogenesis may also rewire intracellular signaling networks. To test this concept, we asked
whether IL-12 provides an intrinsic advantage to B16F0 melanoma cells. Functionally,
stimulation with IL-12 promoted the survival of B16F0 cells that were challenged with a
cytotoxic agent. We also explored a mechanistic basis for the functional results by surveying
the phosphorylation intracellular proteins involved in canonical IL-12 signaling, STAT4, and
cell survival, Akt. In contrast to T cells that exhibited a canonical response to IL-12 by
phosphorylating STAT4, IL-12 stimulation of B16F0 cells phosphorylated both STAT4 and
Akt. Collectively, the data suggests that B16F0 cells have shifted the intracellular response
to IL-12 from engaging immune surveillance to favoring cell survival. In short, identifying
how signaling networks are rewired can guide therapeutic strategies to restore homeostasis.
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1.1.

INTRODUCTION
The response of the different cell types present within tissues, such as T cells and

Langerhans cells within the epidermal layer of skin, is coordinated by the extracellular
release of protein signals. One such extracellular signal is the cytokine Interleukin-12 (IL12) (Colombo 2002). IL-12 is produced by antigen presenting cells, like Langerhans and
Dendritic cells, to boost natural killer (NK) and cytotoxic T lymphocyte (CTL) activity and to
polarize T helper cells towards a type 1 phenotype (Athie-Morales 2004). Activating NK,
CTLs and type 1 T helper cells play important roles in controlling viral infections and
defending against malignancy. Towards this aim, local delivery of IL-12 to the tumor
microenvironment has been shown to promote tumor regression in both mouse models and
human melanoma (Chinnasamy 2012, Choi 2011, Koneru 2015, Seo 2011, Tatsumi 2003,
Zhang 2015, Zhao 2011).
Inside the cell, these extracellular signals are processed through a series of proteinprotein interactions that transmit this information from the cell membrane to the nucleus to
orchestrate a cellular response. In the case of IL-12, these extracellular signals are
transduced by the canonical Janus-Kinase (JAK)-Signal Transducer and Activator of
Transcription (STAT) signaling pathway (Murray 2007). The IL-12 receptor, composed of a
β1 and β2 subunit, lacks intrinsic enzymatic activity and forms a complex with two JAKs,
JAK2 and Tyk2.

Autophosphorylation of the receptor complex results in binding and

activation of STAT4. Phosphorylated STAT4 dimerizes and then translocates to the nuclear
to function as a transcription factor (Watford 2004). As a transcription factor, STAT4
promotes the expression and release of Interferon-gamma (IFN-γ) (Yamamoto 1994), which
upregulates MHC class I antigen presentation (Gaczynska 1993). An increase in antigen
presentation enables CTLs to target and kill virally infected and malignant cells present
within the tissue (Restifo 1995).
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While most of our understanding of how information is transmitted between cells is
based on normal biology, cancer cells arise through a process of mutation and selection
(Bignell 2010, Byrne-Hoffman 2015). This implies that during oncogenesis cancer cells
develop ways to block these extracellular signals or rewire intracellular signaling pathways
to gain a fitness advantage (Heidel 2015, Kvitek 2013). Following from this premise, the
mouse melanoma cell line B16F0 overexpresses one component of the IL-12 receptor,
IL12RB2, to form a cytokine sink for IL-12, which can deprive neighboring immune cells of
this important antitumor cytokine (Kulkarni 2012). As rewiring of intracellular cell signaling
networks is another way that tumor cells can gain advantage, the objective of this study was
to assess whether IL-12 provides an intrinsic advantage to B16F0 tumor cells. We
hypothesized that overexpression of IL12RB2 in melanoma cells, such as the mouse model
B16F0, has an intrinsic benefit for tumor cell survival.

To test our hypothesis, we

investigated the copy number of IL12R subunits, IL12RB1 and IL12RB2, on the surface of
a mouse model of “normal” melanocytes and two melanoma models, B16F0 and Cloudman
S91, and compared that to the expression of the receptor on the surface of an IL12dependent mouse T helper cell model, 2D6. We also observed the cytotoxic activity of small
molecule inhibitor drug imatinib on melanoma cells, and found that IL-12 enhanced cell
viability in the presence of this cytotoxic agent. Finally, we explored a mechanistic basis for
these functional assay results by surveying the activation intracellular proteins involved in
canonical IL-12 signaling, STAT4, and cell survival, Akt.
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1.2. RESULTS
Inspired by our previous observation of an increase in IL12RB2 expression in the
B16F0 cell line, we first asked whether the subunits of the IL12R are similarly upregulated
in other melanoma cell lines that do not depend on IL-12 for their growth and proliferation.
We compared two mouse melanoma cell lines, B16F0 and Cloudman S91, with Melan-A
cells, a model of “normal” melanocytes. The 2D6 T cells, a mouse type 1 T helper cell line,
were used as a positive control for IL12R expression (Kulkarni 2012).

IL12RB1 and

IL12RB2 abundance was assayed by flow cytometry and calibrated to copy number using
antibody calibration beads (Figure 1.1).
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Figure 1.1. IL-12RB2 is Overexpressed in Melanoma Cell Lines versus T Cells.
Components of the IL-12 receptor are differentially expressed in mouse melanoma
cell lines compared to T helper 2D6 cells. IL12RB1 (left panels) and IL12RB2 (right
panels) expression in B16F0 melanoma (a), Cloudman S91 (b), Melan-A “normal”
melanocytes (c), and 2D6 Th1 T helper cells (d), were assayed by flow cytometry.
Antibody-binding calibration beads were used to determine copy numbers. No stain
samples were used as negative controls (gray shaded curves).
representative of at least three biological replicates.
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Results

In 2D6 cells, IL12RB1 and IL12RB2 were present in almost a 2:1 copy ratio, with
43,000 copies of IL12RB1 and 19,500 copies of IL12RB2 and consistent with previous
findings (Kulkarni 2012). Interestingly, all three melanoma-related cell lines stained brightly
for IL12RB2. The copy number of IL12R2 was 1.5 times higher in the melanoma cell line
versus the “normal” melanocyte line, where the Cloudman S91 and B16F0 cell lines
expressed over 330,000 copies of IL12RB2 and Melan-A cells had 214,000 copies. In
contrast, IL12RB1 abundance was barely detectable in all three cell lines, as staining was
similar to the unstained controls. Only the B16F0 cell line was quantified at 1000 copies,
while the Melan-A and Cloudman cell lines were below the detection level of 200 copies per
cell. These data suggest that expression of components of the IL-12 receptor, IL12RB1 and
IL12RB2, are differentially regulated in mouse cell models of melanoma compared with T
cells. This differential regulation is manifested as a high copy number of IL12RB2 and an
absence of IL12RB1, such that copies of the heterodimeric IL-12 receptor are limited.
While creating a cytokine sink by overexpressing IL12RB2 provides an indirect
survival advantage to malignant melanocytes, we also wondered whether overexpression
of IL12RB2 provides a direct survival advantage to malignant melanocytes. To test for an
intrinsic survival advantage, we used an apoptosis and necrosis assay to assess cell viability
during a chemotherapy challenge with imatinib in the B16F0 melanoma (Figure 1.2) in
combination with an IL-12 rescue. We used imatinib, as it is currently being investigated as
a possible chemotherapy for metastatic melanoma (Carvajal 2011, Hodi 2013).
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Figure 1.2. IL-12 Rescues B16F0 Cells from Imatinib. B16F0 melanoma cells can be
rescued from the cytotoxic effect of imatinib by IL12p70. Cell viability in response to
different concentrations of IL12p70 and imatinib was assayed by flow cytometry,
whereby representative results for specific concentrations (a: No IL12p70, No
imatinib; b: 20 μM imatinib; c: 200 ng/mL IL12p70 and 20 μM imatinib) are shown. Cell
events were identified based on forward and side scatter properties (enclosed in red
curve in left panel). Annexin V and PI staining were used to identify viable cells (PI
negative, Annexin V negative), cells undergoing apoptotic (Annexin V positive, PI
negative) and necrotic (Annexin V negative, PI positive) cell death, and cells in late
stages of apoptosis (Annexin V positive, PI positive).

(d) Using the collective

observed data (symbols), a mathematical model was used to estimate the increase in
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EC50 of imatinib in the presence of IL12p70. The curves trace the corresponding
maximum likelihood predictions for each experimental condition. A Markov Chain
Monte Carlo approach was used to estimate the model parameters. The posterior
distributions in the EC50 of imatinib and the rescue effect of IL-12 (α) are shown in
the bottom panels.

To determine whether IL-12 could “rescue” the melanoma cells from the cytotoxic
effects of chemotherapy, we incubated the cells with three different concentration of IL12p70
(40, 100, or 200 ng/mL) for 18 hours, which correspond to concentrations of IL12p70 in the
serum of various mouse models at approximately 3-134 ng/mL (Schulz 2007). We then
treated with three different concentrations of imatinib (5, 10, or 20 µM) for 24 hours, with
0.1% DMSO in DPBS serving as a vehicle control. Cell viability was assayed by flow
cytometry, whereby cells were identified based on forward and side scatter characteristics.
Gating on “cells”, the presence of Annexin-V staining on the cell surface and no PI staining
indicates a cell undergoing apoptosis, while cells that are positive for PI and negative for
Annexin-V indicates a cell that underwent necrotic cell death.
At baseline, the viability of B16F0 cells was greater than 90%. Upon treatment with
imatinib, the viability was decreased in a dose-dependent manner, as expected. At 24
hours, very few of the cells were observed during the early stages of apoptosis (AnnexinV+, PI-) and the majority of non-viable cells either underwent necrotic cell death (AnnexinV-, PI+) or were in the late stages of apoptotic cell death (Annexin-V+, PI+). The addition
of IL12p70 reduced the cytotoxic efficacy of imatinib such that the maximum shift in viability
of cells pre-treated with IL12p70 before imatinib challenge was about 15%. To quantify the
effects of imatinib and IL12p70 on the viability of the B16F0 cells, we analyzed the data
using a mathematical model and inferred the model parameters using a Markov Chain
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Monte Carlo (MCMC) approach. In theory, the model is identifiable as there are more data
points (16) than model parameters (3). However, given the non-linear nature of the model,
the MCMC approach was used to assess whether the model parameters could be practically
identified from the available data in addition to estimating parameter values. The MCMC
results suggested that the effective concentration of imatinib (EC50) and the rescue effect
of IL12p70 could be practically identified from the data as they exhibited symmetric bounded
distributions. The posterior distributions provided a median value of the EC50 of imatinib
equal to 40 nM for imatinib and of α equal to 1 (Figure 1.2d). Moreover, the posterior
distributions indicated that the rescue effect of IL12p70 from the cytotoxic actions of imatinib
was significant (p<0.05 that α<0). Quantitatively, a saturating concentration of IL12p70
would increase the EC50 for imatinib by 100% (median value of α=1), thereby shifting the
imatinib dose-response curve to the right. While cell viability was assayed after only 24
hours, the observed difference implies that, over a 1 week period, tumor load would increase
by about 10-fold in the IL-12 pre-treated cells versus chemotherapy alone.
To confirm the role of IL12RB2 in the “rescue” effect of IL-12 to cytotoxic stress with
imatinib, we knocked down IL12RB2 in the B16F0 cell line using a CRISPR-Cas9 construct
(Figure 1.3a). Generally, knockdown clones grew at similar rates, showed minor differences
in color, and displayed similar phenotypes to the wild-type cell line. Knockdown of IL12RB2
was confirmed by flow cytometry. To compare the functional response, wild type (wt) and
IL12RB2 knockdown (KD) B16F0 cells were treated with increasing concentrations of
imatinib for 12 hours and pre-stimulation with 100 ng/mL IL12p70 overnight was included
as a second independent variable. Cell viability was assessed using an ATPlite assay.
Consistent with data shown in Figure 1.2, imatinib dose-dependently reduced viability in the
wild-type B16F0 cell line that was prevented with pre-treatment with IL-12 (Figure 1.3b). The
rescue effect of IL-12 was most pronounced at the higher concentrations of imatinib. In
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comparison, imatinib also dose-dependently reduced viability of the IL12RB2 knockdown
cells but IL-12 provided no benefit (Figure 1.3c). Visually, we also noticed that IL-12 had no
effect on preventing cell detachment or inhibiting growth in IL12RB2 KD cells. Collectively,
the results suggested that IL12p70 enhances the survival of B16F0 cells in the presence of
cytotoxic stressors, like imatinib, and its effect is dependent on IL12RB2 expression.

Figure 1.3. IL12RB2 Knockdown in B16F0 Decreases the Survival Benefit of IL12p70.
(a) Flow cytometry was used to compare IL12RB2 expression inB16F0 cells edited

- 30 -

using a CRISPR/Cas9 construct to knockdown IL12RB2 (IL12RB2 KD – black
histogram) with wild-type (wt – red histogram) B16F0 cells. Unstained B16F0 cells
were used as a negative control (grey shaded histogram). Cell viability was assessed
using an ATPlite assay in wild-type (b) and IL12RB2 KD (c) B16F0 cells following
treatment with the indicated concentration of imatinib with or without pre-treatment
with 100 ng/ml of IL12p70. Results are summarized by a bar graph (ave +/- stdev)
overlaid with individual results (x’s) that represent at least 5 independent biological
replicates for each condition. Statistical significance in the difference in viability
upon IL12p70 treatment for a given imatinib concentration was assessed using a twotailed homoscedastic t-Test, where ** indicates a p-value < 0.005 and * indicates a pvalue < 0.05.

Given the severe imbalance of IL-12 receptor expression in B16F0 cells, it was
unclear what signals were transduced in B16F0 cells in response to IL12p70 stimulation.
Moreover, activating STAT4, which plays a role in Interferon-γ gene expression and not
survival, is thought to be the canonical signaling response to IL12p70. To investigate, we
assayed the phosphorylation of STAT4, a canonical signal transducer, and Akt, a noncanonical signal transducer involved in promoting cell survival and therapeutic resistance
(Davies 2012), in response to IL12p70 stimulation in both live B16F0 and 2D6 cells by flow
cytometry (Figure 1.4). The 2D6 T helper cell line was used as a model for canonical IL-12
signal transduction. Following 12-24 hours of preconditioning in media free of IL-12 (2D6
only) and serum (2D6 and B16), we stimulated B16F0 and 2D6 cells with increasing
concentrations of IL12p70 (0, 40, 100, and 200 ng/mL; data shown for the 100ng/mL
treatment). Pre-conditioning ensured that activation of the IL-12 signaling pathway was due
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to IL12p70, and not due to factors in the serum or basal IL-12. PBS was used as a negative
vehicle control for both cell lines.

Figure 1.4. B16F0 Melanoma Cells Transduce Non-Canonical Signals in Response to
IL-12 Stimulation. Live (top panel) B16F0 (A) and 2D6 (B) cells were stimulated with
100 ng/mL IL-12 and assayed for STAT4 (middle panel) and Akt (bottom panel)
phosphorylation by flow cytometry.

IL-12 stimulated cells (blue curves) were

compared with unstimulated (black curves), no stain (gray shaded curves) and
positive controls (red curves).

For 2D6 cells, a positive control was obtained

following a culture without IL12p70 for 12 hours, followed by stimulation with 40
ng/mL IL-12 for 3 hours. For B16F0 cells, a positive control was obtained following
culture without serum for 12 hours, followed by stimulation with media containing
10% FBS. Panels C and D summarize the observed response across all of the
experimental groups and replicates.
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Both 2D6 and B16F0 cells phosphorylated STAT4 in response to IL12p70
stimulation (p<0.0001 for 2D6 and p<0.05 for the B16), with the response more pronounced
in 2D6 cells, as expected. Basal STAT4 phosphorylation was minimal in both cell lines for
the vehicle only-treated controls. In terms of Akt phosophorylation, the B16 melanoma
showed a marked activation of Akt within 3 hours at all concentrations of IL12p70 tested,
with a significant increase (p<0.05) in pAkt with 100 ng/mL IL12p70 treatment. In contrast,
2D6 cells exhibited no significant shift in phosphorylation of Akt above baseline in response
to IL-12 treatment. Pre-conditioning cells in the absence of serum was critical to observe
differences in Akt phosphorylation.
To determine whether Akt activation in the B16 melanoma line was specific, we
repeated the experiment and used a Western Blot assay to determine basal levels of Akt
and test several inhibitors against the IL12p70-induced effect on Akt phosphorylation
(Figure 1.5). To serve as a negative control and to determine whether the PI3K pathway
may be cross-activated in response to IL-12 stimulation, we used a PI3K inhibitor LY294002.
In addition, we used a selective pAkt inhibitor, MK-2206, to investigate whether the observed
effect was solely through possible direct activation of Akt by the IL-12 receptor. Two different
phosphorylation sites on Akt were assessed, threonine 308 (Thr308) and serine 472/473
(Ser472/473). We also measured total Akt, and β-actin was used as a loading control. We
found no change in phosphorylation of Thr308 in response to IL-12 stimulation, whereas
baseline phosphorylation was turned off by both LY294002 and MK-2206. However, IL-12
stimulation produced a marked increase in phosphorylation of the Ser472/473 site, and
again, phosphorylation was blocked by both the PI3K and Akt-selective inhibitors.
Collectively, the results suggest that IL12p70 provides a survival advantage to B16F0 cells
and that IL12p70 induced a different cellular response in B16F0 cells compared to 2D6 T
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cells, whereby phosphorylation of Akt, a non-canonical signal transducer that is associated
with enhanced cell survival is favored over STAT4, which is the canonical signal transducer.

Figure

1.5.

IL12p70

Differentially

Phosphorylates

Akt.

IL12p70

stimulated

phosphorylation of Akt on serine 472/473 (Ser472/473) but not threonine 308 (Thr308)
in B16F0 cells.Activation of Akt by IL12p70 (100 ng/mL) in B16F0 was probed using
antibodies that recognized phosphorylation at serine 472/273 (A) and threonine 308
(B). IL-12-stimulated cells were compared against unstimulated (negative control),
10% FBS stimulated (positive control), and cells stimulated with IL-12 plus PI3K
inhibitor LY294002 (IL12+LY), FBS plus PI3K inhibitor (LY294002), or IL-12 plus pAkt
selective inhibitor (IL12+MK). Beta-actin and total Akt serve as loading controls.
Results are representative of at least 3 replicates.
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To extend our focus beyond mouse cell models, we also wondered whether similar
patterns of gene expression are observed in human melanoma. Towards this aim, we
determined whether IL12RB1 and IL12RB2 gene levels are significantly different in human
melanoma and are comparable to our protein level findings in mouse models of melanoma
(Table 1.1). From data retrieved from Oncomine, we found that IL12RB2 is significantly
upregulated by approximately 5-fold in human melanoma, compared to normal tissue and
at a higher level than IL12RB1, which was also elevated by approximately 2.26 fold,
compared to normal. Benign nevus samples did not produce significant differences in
IL12RB1 or IL12RB2 gene levels. While normal tissue samples were not included in the
Cancer Genome Atlas (TCGA) study, there was no significant difference in the levels of
IL12RB2 between the primary or metastatic sites. However, IL12RB1 was significantly
upregulated by more than 1.5 times in metastatic versus primary tumors. These results
state that significant gene level changes in the IL12R subunits occur within development of
human melanoma and are exacerbated in metastatic sites versus primary tumors. Because
the TCGA and Oncomine data sets reflect homogenized tissue samples that may contain a
mixture of tumor and immune cells, we also examined data sets from the Cancer Cell Line
Encyclopedia (CCLE), which reflects mRNA expression in cellular models of human cancer.
In the reported melanoma cell lines, expression of IL12RB2 was significantly greater than
IL12RB1, such that the ratio of IL12RB2 to IL12RB1 gene expression was 1.06 (p<0.028,
ratio<1) (Table 1.1).
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Table 1.1. IL-12 Pathway Genes are Upregulated in Human Melanoma. Comparison of
IL12RB1 and IL12RB2 expression in normal, nevus, and melanoma human tissue
samples provided from the Oncomine database (Talantov) shows a 2.26-fold and 5fold difference in IL12RB1 and IL12RB2 expression, respectively, between normal
and melanoma cells. Similarly, the data obtained from the TCGA database shows
almost a 1.6-fold difference between metastatic and primary tumor IL12RB2 gene
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expression. Ratios of IL12RB2 to IL12RB1 gene expression in human melanoma cell
lines were calculated from TCGA, Oncomine, and Cancer Cell Line Encyclopedia.
Ratios were normally distributed with a mean of 0.76, 2.41, and 3.71 (p<0.0001) for
normal, nevus, and melanoma samples in Oncomine, respectively; 28.5 for metastatic
tumors and 36.24 in primary tumors for TCGA samples, 1.055 and (p<0.05, ratio>1)
for homogeneous melanoma samples in CCLE. Note: Samples were not available
on TCGA platform for statistical comparison of primary and metastatic tumors to
normal.

1.3. DISCUSSION
Given the importance of IL-12 in promoting type 1 anti-tumor immune response, we
had previously observed that, by overexpression one component of the IL-12 receptor
IL12RB2, B16 melanoma cells could create a “cytokine sink” and deprive tumor-infiltrating
lymphocytes of this local signal to sustain an anti-tumor response (Kulkarni 2012). Here,
our results indicate that IL-12 can act directly on B16 melanoma cells to phosphorylate
STAT4 (Figure 1.4a and 1.4c), although less pronounced as observed in T helper cells
(Figure 1.4b and 1.4d). In contrast to T helper cells, IL-12 provided an intrinsic survival
advantage to B16 melanoma cells by engaging the non-canonical signal transducer Akt,
that is B16 cells re-wired the canonical immune cell response to IL-12 to enhance cell
survival. The survival benefit of IL-12 appears to be mediated through IL12RB2, as knock
down of IL12RB2 abrogated the effect. This observation indicates that melanoma cells may
rewire signal transduction to create a non-canonical signaling pathway to promote survival
in response to cytokines within the tumor environment.
As summarized in Figure 1.6, we propose a mechanism by which rewiring of the
canonical IL-12 pathway could occur that is initiated by IL-12 mediated homodimerization of
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IL12RB2. IL-12 has been shown to promote a low but significant level of homodimerization
of IL12RB2 subunits (Collison 2012).

Overexpression of IL12RB2 may make this

association more likely to occur in the melanoma cell line.

Following IL12RB2

homodimerization, the receptor associated Janus kinase, JAK2, interacts to promote cross
phosphorylation and activation (Kershaw 2013). Activated JAK2 can then recruit and
activate PI3K via the p85a subunit (Fuhrer 1996, Yamada 2012). Activated PI3K can then
activate Thr308-primed Akt via phosphorylating the Ser 472/473 loci. Our findings support
the direct role of PI3K in the observed phosphorylation of Akt to affect cell survival, as
inhibitors directed against PI3K pathway like LY294002 ameliorated this effect.

Figure 1.6. Canonical versus Non-Canonical IL-12 Pathways. Schematic diagram
illustrating the different in canonical versus non-canonical response to IL-12. (a) The
canonical IL-12 pathway is triggered by (1) ligand-mediated heterodimerization of the
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receptor subunits IL12RB1 and IL12RB2. (2) Formation of the receptor complex
promotes the phosphorylation of receptor associated kinases JAK2 and TYK2 and of
a signal transducer binding site on the cytoplasmic tail of IL12RB2. (3)
Phosphorylation of this IL12RB2 binding site attracts STAT4 that is subsequently
phosphorylated by JAK2. (4) Phosphorylated STAT4 dimerizes and translocates into
the nucleus to initiate STAT4-mediated transcription that promotes cell proliferation
and Interferon-gamma production. (b) The non-canonical IL-12 pathway is triggered
by (1) IL-12-mediated homodimerization of IL12RB2 subunits. (2) Homodimerization
of IL12RB2 activates the JAK2 receptor associated kinases, which in turn (3) recruit
and activate PI3K via the p85a subunit. (4) Activated PI3K then phosphorylates
Thr308-primed Akt at the Ser 472/473 loci, which engages the canonical Akt response
that includes enhanced survival.

Rewiring of signaling pathways during oncogenesis is emerging as an important
concept in cancer biology (Pawson 2007). For instance, a recent systems biology study
across all known human kinases showed there are six types of network-attacking mutations
that perturb signaling networks to promote cancer, including mutations that dysregulate
phosphorylation sites to cause constitutive activation or deactivation, rewire networks
through upstream or downstream interactions, and dysregulate network dynamics by
activated or deactivating nodes of response (Creixell 2015). As for precedence of noncanonical signaling within the JAK-STAT pathway, STAT3 has been reported as a noncanonical activator of the NF-κB pathway to promote myeloid-derived suppressor cells in
the tumor microenvironment (Yu 2014). Beside oncogenic fusion proteins, increased
abundance of intracellular signaling proteins through either copy number amplifications or
epigenetic changes can also create non-canonical protein interactions that could redirect
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the flow of intracellular information (Klinke 2010). Knowing the basis for cancer cell rewiring
can be used for therapeutic advantage. For instance, the non-canonical use of signaling
cross-talk downstream of the EGF receptor sensitized resistant triple negative breast
cancers to DNA-damaging chemotherapies by inhibition of EGFR (Lee 2012). Similar
approaches could be applied to circumvent rewiring of the IL-12 pathway.
While additional studies may help clarify the mechanistic details and generalize the
finding, several prior studies lend support that IL-12 can elicit a direct response in tumor
cells and that the IL-12 receptor can activate non-canonical signaling elements. In vitro, IL12 had a direct effect to upregulate MHC complexes on human melanoma cell lines (Yue
1999).

A similar response was not observed in mouse tumor cell lines although the

concentrations of IL-12 used were rather low (0.3 – 1 ng/ml) (Su 2001). Su et al. also
reported that the expression of IL12RB1 was absent in B16 cells compared to other mouse
tumor cell lines. However, results for IL12RB2 are inconclusive as IL12RB2 amplicons were
unable to be observed in any of the tumor cell lines. IL-12 did activate NF-κB in two cell lines
(MC-38 and Colon-26-NL-17); yet, this could be an artifact of the platform used for producing
recombinant IL-12, such as endotoxin derived from E coli (Schwarz 2014). Using the B16
model in IL12RB2 KO mice, Airoldi et al. show that IL-12 directly acts on B16 tumor cells
such that, after 12 days, tumor growth is reduced by a factor of 2.5 (Airoldi 2007). This
difference in tumor growth was attributed to a release of anti-angiogenic factors by B16 cells
following IL-12 stimulation; yet, a specific mechanism for this observation remains unclear.
While this may seem at odds with our observations, this in vivo study doesn’t rule out the
possibility that IL-12 may have a pleiotropic effect on tumor cells such that it may both
promote survival in the presence of cytotoxic stressors and inhibit angiogenesis. Of note,
cellular stress, such as hypoxia, is an important trigger for angiogenesis (Krock 2011). In
terms of signal transducers, Goreilik et al. observed the activation of both Akt and STATs
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by treating human ovarian cancer cell lines with 40 ng/ml of IL12p70 (Gorelik 2004).
Alternatively another cytokine receptor type could associate with IL12RB2, which contains
binding sites for JAK2 and STAT4 and primarily interacts with the IL12p35 subunit of
IL12p70. For instance, IL-35 signals through a receptor comprised of the IL12RB2 and the
gp130 subunits, but does not bind nor transduce signals in response to IL12p70, which
binds cytokines IL-6, IL-11, and several other cytokines to activate STATs (Collison 2012).
In summary, IL-12 provides an important function in coordinating an anti-tumor
immune response. In melanoma, overexpression of one component of the IL-12 receptor,
IL12RB2, by malignant melanocytes may not only serve to deprive immune cells of this
important cytokine, but malignant melanocytes may also use IL-12 as a means of activating
cell survival pathways. Supported by prior studies, we present evidence showing that IL-12
increased the dose of imatinib chemotherapy needed to induce cell death in B16 melanoma
cells and that IL-12 activated a non-canonical cell survival protein, Akt, in a melanoma cell
line, but not in the 2D6 T helper cell line. While subsequent studies will help clarify the
mechanistic details to improve the translational impact, these studies highlight the
importance of non-canonical pathway activation in cancer.

1.4. METHODS
1.4.1. Cell Culture
B16F0 mouse melanoma (ATCC, Manassas, VA), Cloudman S91 mouse melanoma
(ATCC) and Melan A mouse melanocytes (V. Hearing, National Cancer Institute, Bethesda,
MD) were cultured at 37.5ºC with 5% CO2. Complete medium for B16F0 cells consisted of
Dulbecco’s Modified Eagle Medium (DMEM, Corning, Manassas, VA) supplemented with
10% heat-inactivated fetal bovine serum (FBS-HI, Corning), 1% penicillin-streptomycin
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(Pen-Strep, Corning), and L-Glutamine (2 mM final concentration, Corning). Cloudman S91
complete culture medium was DMEM with 10% FBS-HI and 1% Pen-Strep. Melan A culture
medium was DMEM with 10% FBS, 20 mM HCl, 10mM HEPES (Corning), 1% Pen-Strep,
and fresh 12-O-tetradecanoyl phorbol-13-acetate (TPA; 200 nM; Sigma-Aldrich, St. Louis,
MO) and phenylthiourea (PTU; 200µM; Sigma-Aldrich). Cells were detached using either
Trypsin-Versene or magnesium and calcium-free Dulbecco’s Phosphate-Buffered Saline
(DPBS, Corning).

1.4.2 Apoptosis and Necrosis Assay
Cells were plated at a density of 1x105 cells/well in a 12 well tissue culture plate (BD
Falcon, BD Biosciences, San Jose, CA). Cells were allowed to adhere to the plate for 12
hours prior to the beginning of the experiment, then pre-treated with complete culture media
with a final concentration of 40, 100, or 200 ng/mL IL12p70 (R&D Systems, Minneapolis,
MN). After 18 hours of pretreatment, cells were treated with 0, 5, 10, or 20 µM imatinib
(Cayman Chemical, Ann Arbor, MI). A 0.1% DMSO vehicle control in complete media was
used as a negative control, while cells heated to 50°C for 5-10 minutes served as a positive
control cell death. After 24 hours of incubation with imatinib or other treatment, cell viability
was assessed using either a flow cytometry-based assay or an ATPlite assay (PerkinElmer,
Shelton, CT), which was performed according to the manufacturer’s instructions. For the
flow cytometry-based assay, cell media and floating cells were pooled with cells detached
with DPBS without magnesium or calcium, centrifuged in 15 mL conical tubes at
approximately 250xg, supernatant removed, and cells transferred to a 96 well round bottom
plate (BD Falcon) for staining. Cells were then washed with DPBS with magnesium and
calcium. After centrifuging at approximately 250xg again and removing the supernatant,
cells were then stained with an apoptosis and necrosis staining kit (ABD Serotech, Bio-Rad,
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Raleigh, NC) according to manufacturer’s instructions. Samples were then analyzed shortly
thereafter by flow cytometry on a BD LSR Fortessa.

Data was analyzed in the BD

FACSDiva 3.0 software and in Microsoft Excel. For the ATPlite assay, pre-treated cells were
lysed with 50μL/well of mammalian cell lysis solution, followed by 5 min. shaking. The
substrate solution was added (50μL/well), shaken for another 5 min., and incubated 10 min.
at room temperature protected from light. Finally, the luminescence was measured using a
modulus microplate multimode reader (Turner BioSystems, Promega, Madison, WI). B16F0
cells cultured in base media alone and exposed to 10% DMSO were included as controls.
Statistical significance in the difference in viability upon IL12p70 treatment for a given
imatinib concentration was assessed using a two-tailed homoscedastic t-Test, where a pvalue less than 0.05 was considered significant.

1.4.3 Flow Cytometry
Cells were grown at a density of 1x105 cells/well in a 12-well tissue culture plate if
adherent (B16F0, Melan-A, Cloudman S91) or in a 96 well round bottom plate if nonadherent (2D6) (BD Falcon).

At each time point, adherent cells were detached from the

plate with Trypsin-EDTA or DPBS without calcium/magnesium. For IL12RB1 and IL12RB2
copy number, cells were stained for 30 minutes with Yellow or Violet Live/Dead Fixable Stain
(BD Biosciences), fixed with Lyse/Fix Buffer (BD Biosciences), then surface stained for PEIL12RB1 (Clone 114, BD Biosciences) and AlexaFluor 488-IL12RB2 (Clone 305719, R&D
Systems, Minneapolis, MN) antibodies separately. Counting beads (Bangs Laboratories,
Fishers, Indiana) were also stained with IL12RB1 or IL12RB2 antibody within the same
experiment and used to assess receptor copy number. Fluorescent spillover was assessed
using single stain controls for IL12RB1 and IL12RB2 antibodies and Live/Dead stains. To
assay intracellular activity of STAT4 and Akt, B16F0 and 2D6 cells were starved of FBS and
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IL-12p70 for 12-24 hours after plating and then treated for 1hr or 3hr with 100 ng/mL IL12p70 or vehicle. Positive control cells were treated with 10% FBS and 40 ng/mL IL-12p70.
Cells were then stained using Violet Fixable Live/Dead (Invitrogen, Carlsbad, CA) to assess
cell viability, and then fixed (BD Biosciences Lyse/Fix), permeabilized with Perm Buffer III
(BD Biosciences), blocked with Mouse IgG (1:100, concentration, Jackson Labs, West
Grove, PA), and intracellular stained with AF647-pAKT (Clone M89-61) and AF488-pSTAT4
(Clone 38) (BD Biosciences).

Cells were stored at 4°C in PBS+ 0.1% Sodium Azide

(PBSaz) before analyzing via flow cytometry. Cells were analyzed using the BD LSR
Fortessa flow cytometry analyzer, FCSExpress, and BD FACSDiva 3.0 software. Following
acquiring 20,000 events on average, forward and side scatter were used to gate cell
populations. Live-Dead staining was used as a gate for live cells.

1.4.4. CRISPR/Cas9 Constructs, Transfection and Cloning Validation
Two vectors were prepared by GenScript (Piscataway, NJ) with puromycin
resistance

genes

and

the

flanking

guide

RNA

(gRNA)

sequences

TCCGCATACGTTCACGTTCT and AGAATTTCCAAGATCGTTGA and transfected into
wild-type B16F0 cells using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA).
Transfection was confirmed via microscopy visually using a green fluorescent protein
control. Derivatives of the B16F0 cell line were obtained from single clones isolated using
puromycin selection and single cell plating.

Approximately 10-25% of clones were

estimated at having some level of IL12RB2 knockout, which was confirmed by flow
cytometry with PE-IL12RBtotal kT2 (R&D Systems).

1.4.5 Western Blot
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B16 and 2D6 cells were grown in complete media at a density of 5x105 cells/well in
6 well plates 24 hours before the beginning of the experiment. At 12 hours prior, cells were
starved of FBS and IL12p70. One hour before start of experiment, cells were treated with
control solution, PI3K inhibitor LY294002 (50 µM, Cell Signaling Technology, Danvers, MA),
or with Akt inhibitor MK-2206 (2.4 ug/mL or 5 µMol/L, Cayman Chemical, Ann Arbor, MI).
Cells were then treated with 100 ng/mL IL12p70 at t=0 or stimulated with FBS as a positive
control. After 30 minutes or 3 hours, cells were collected for cell lysates for western blot
analysis for total Akt (1:1000, #9272, Cell Signaling Technology), pAkt (1:1000, Ser473
#9271, Thr308, #9275, Cell Signaling Technology), and β-actin (1:1000, Clone AC-74,
Sigma Aldrich, St. Louis, MO). The cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 2 mM EDTA, 1 mM NaVO4, 10 mM NaF, and protease inhibitors),
and the protein concentration in the lysates was determined by a spectrophotometer. Equal
amounts of the lysates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE)
and the immunoblotting was performed with use of the primary antibodies listed above and
secondary antibodies conjugated to horseradish peroxidase (Jackson ImmunoResearch,
West Grove, PA). Proteins were visualized by chemiluminescence.

1.4.6 Data Analysis and Statistics
The impact of IL-12 on decreasing the cytotoxic efficacy of imatinib was inferred from
the data using a mathematical model:

𝐿𝑖𝑣𝑒 𝐶𝑒𝑙𝑙𝑠 % = 100 ∙

1−

𝐶/0
𝐶/0 + 𝐸𝐶34 ∙ 1 + 𝛼
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𝐶/678
𝐶/678 + 𝐾:

where CIm is the concentration of imatinib, CIL12 is the concentration of IL12p70, EC50 is the
effective concentration required to elicit a 50% drop in viability, Kd is the equilibrium binding
constant of IL12p70, and a is a parameter that quantifies the impact of IL12p70 is shifting
the EC50 of imatinib. As described previously (Klinke 2014), a Markov Chain Monte Carlo
approach based on a Metropolis-Hasting algorithm was used to obtain converged Markov
Chains that represent samples from the distributions in the model parameters that were
consistent with the data, that is posterior distributions in the model parameters. The posterior
distribution in parameter a was used to infer whether the effect was greater than zero and
significant. A p-value (P(a<0 |M, Y)) of less 0.05 was considered as significant, that is the
data support that IL12p70 provides a rescue effect to imatinib. The significance associated
with differences in STAT4 and Akt phosphorylation was assessed using a two-tailed
homoscedastic t-Test in GraphPad Prism 7, where a difference with a p-value of less than
0.05 was considered significant and not explained by random noise.
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CHAPTER 2: BREAST CANCER SECRETOMES CONTAIN EXOSOMES TARGETING
IMMUNE FUNCTION

Challenges in demonstrating durable clinical responses to molecular-targeted
therapies have sparked a re-emergence in viewing cancer as an evolutionary process. In
somatic evolution, cellular variants are introduced through a random process of somatic
mutation and are selected for improved fitness through a competition for survival. In
contrast to Darwinian evolution, cellular variants that are retained may directly alter the
fitness competition. If cell-to-cell communication is important for selection, the biochemical
cues secreted by malignant cells that emerge should be altered to bias this fitness
competition. To test this hypothesis, we compared the proteins secreted in vitro by two
human HER2+ breast cancer cell lines (BT474 and SKBR3) relative to a normal human
mammary epithelial cell line (184A1) using a proteomics workflow that leveraged twodimensional gel electrophoresis (2DE) and MALDI-TOF mass spectrometry. Supported by
the 2DE secretome maps and identified proteins, the two breast cancer cell lines exhibited
secretome profiles that were similar to each other and, yet, were distinct from the 184A1
secretome. Using protein–protein interaction and pathway inference tools for functional
annotation, the results suggest that all three cell lines secrete exosomes, as confirmed by
scanning electron microscopy. Interestingly, the HER2+ breast cancer cell line exosomes
are enriched in proteins involved in antigen-processing and presentation and glycolytic
metabolism. These pathways are associated with two of the emerging hallmarks of cancer:
evasion of tumor immunosurveillance and deregulating cellular energetics.
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2.1 INTRODUCTION
De novo and emergent resistance to many, if not all, molecular-targeted therapies
in cancer prompts a re-emergence of the view of cancer as a process of somatic evolution
(Greaves and Maley, 2012; Klinke, 2013; Merlo et al., 2006). Environmental mutagens alter
the genome of somatic cells. Recent efforts to sequence cancer genomes highlight a
prolonged period of DNA damage (e.g., Pleasance et al., 2010). Intracellular mechanisms
aim to repair DNA damage but inevitably some mutations escape from this process. These
mutations provide a rich source of neoantigens that can be recognized by the immune
system of the host and, as a consequence, result in removal of the cell from the population
contained within a tissue (Matsushita et al., 2012). Mutations can also alter how a cell
interprets and responds to extracellular cues present within the tissue microenvironment
(Klinke, 2010). As these mutations are introduced through a random process, some
mutations will improve and other mutations will diminish the ability of a cell to respond
appropriately to these extracellular cues. Ultimately, the fate of newly malignant cells within
a multicellular tissue is determined by their ability to outcompete normal cells for survival.
Conventionally, aspects of this survival competition associated with evolution include the
ability to resist normal cell death signals, the ability to proliferate more rapidly, and the ability
to survive using suboptimal nutrients. Malignant cells that arise have improved ability to
survive given the constraints imposed on the cell by the tissue microenvironment, that is
malignant cells have improved fitness. The collective aspects of this competitive selection
process comprise a selective fitness landscape. In other words, the selective fitness
landscape edits the phenotypic traits associated with emergent malignant variants.
Tissues are comprised of a variety of cell types, each with a finite lifespan and unique
functional role, and constitute a dynamic system. Most dynamic systems contain control
mechanisms to maintain stability, that is homeostasis for a tissue, in the presence of external
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perturbations, as introduced by mutagens (Csete and Doyle, 2002). From this dynamic
control perspective, we can view the fitness landscape as being constructed of a series of
intracellular and extracellular control mechanisms (Klinke, 2013). In the presence of external
perturbations, intracellular control mechanisms aim to maintain the integrity of a cell's
functional programming. In contrast, extracellular control structures act at a population-level
to maintain the dynamic roles that cells play within multicellular tissue structures.
Extracellular control structures include innate and adaptive immunity and involve cell-to-cell
communication. Conventionally, cell-to-cell communication occurs through direct cell-to-cell
contact, such as the presentation of antigens, or through indirect modes that involve the
release of biochemical cues and the binding of these cues to cellular receptors, such as the
release of cytokines by T helper cells. The release of extracellular vesicles is also emerging
as a mechanism for indirect cell-to-cell communication (Thery, 2011). Decades of research
have improved our understanding of how mutations alter these intracellular control
mechanism (Hanahan and Weinberg, 2011). For instance, more than half of all cancers
harbor mutations in p53, a protein that helps control genomic integrity (Hollstein et al., 1991).
Yet, our understanding of how malignant cells manipulate these extracellular control
structures is still emerging (Hanahan and Weinberg, 2011). Selecting for cell phenotypes
that manipulate the selective fitness landscape in favor of malignant cell survival may be
one aspect that differentiates somatic evolution from Darwinian evolution.
To better understand how cell-to-cell communication becomes altered in cancer, a
first order approximation is to assume that the biochemical cues secreted by malignant cell
lines, called the tumor secretome, reflect the editing process associated with oncogenesis.
To test this assumption, we compared the biochemical cues secreted in vitro by cellular
models of breast cancer relative to normal human mammary epithelial cells. For this study,
we focused on two cell models of a subtype of breast cancer that overexpresses HER2, a
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member of the epidermal growth factor family of receptors, which is targeted therapeutically
by the monoclonal antibody trastuzumab (Slamon et al., 2001). These breast cancer cell
lines also vary in their expression in receptors for estrogen (ER) and progesterone (PR).
The BT474 cell line was derived from a HER2+/ER+/PR+ solid invasive ductal carcinoma
of the breast and exhibits high in vitro invasiveness (Lasfargues et al., 1978). The second
cell line (SKBR3) was derived from a pleural effusion breast adenocarcinoma, is
HER2+/ER−/PR−, and exhibits low in vitro invasiveness (Trempe, 1976). These breast
cancer cell lines were compared against the 184A1 cell line, which reflects normal human
mammary epithelium. This secretome comparison is to complement our proteomic analysis
of whole cell lysates from these three breast cancer models (Kulkarni and Klinke, 2012). In
short, we found that the two HER2+ breast cancer cell lines exhibited secretome profiles
that are similar to each other and, yet, are distinct from a human mammary epithelial cell
line secretome and the proteomes of the corresponding whole cell lysates, as supported by
similarities and differences between the 2-D gel secretome maps and lists of identified
proteins. Given the similarities in the breast cancer secretomes, we aimed to infer common
mechanisms by which these cancer cells alter the selective fitness landscape using data
integration sources for functional annotation and validated this functional annotation on an
independent sample using scanning electron microscopy (SEM), an orthogonal approach
to proteomics.
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2.2 MATERIALS AND METHODS

2.2.1

Cell Culture and Sample Preparation
The human breast cancer and normal mammary epithelial cell lines (BT474, SKBR3,

and 184A1) were cultured as described previously (Kulkarni and Klinke, 2012). In summary,
BT474 cells were maintained in supplemented Roswell Park Memorial Institute (RPMI)
1,640 medium (Mediatech, Inc., Herndon, VA) supplemented with 10% (v/v) heat inactivated
fetal bovine serum (FBS) (Hyclone, Inc., Logan, UT), 0.3% (w/v) L-glutamine, 1% (v/v)
penicillin/streptomycin (BioWhittaker, Walkersville, MD) and 10 µg/mL insulin (Sigma, St
Louis, MO); SKBR3 cells were maintained in supplemented Improved Modified Eagle
medium (IMEM) Zn2+ option (Invitrogen) supplemented with 10% FBS and 1%
penicillin/streptomycin; and 184A1 cells were maintained in DMEM/Ham's F-12 (1:1)
medium supplemented with 5% (v/v) horse serum (Invitrogen), 20 ng/mL rhEGF (Promega
Corp, Madison, WI), 10 µg/mL insulin and 0.5 µg/mL hydrocortisone (Sigma). All cell lines
were cultured in a humidified incubator at 37°C and 5% (v/v) CO2. As similarly described in
Kulkarni et al. (2012), serum-free media conditioned by an equal number of cells from each
of the three cell lines were collected following a wash sequence in serum-free media (0 h
sample) and after 48 h. The secretome was enriched in the conditioned media using a
staged centrifugation protocol, as described in Kulkarni et al. (2012), and cleaned-up using
a 2D clean-up kit from GE Healthcare (Cat. 80-6484-51).

2.2.2 Proteomics Workflow
The human breast cancer and normal mammary epithelial cell lines (BT474, SKBR3,
and 184A1) were cultured as described previously (Kulkarni and Klinke, 2012). In summary,
BT474 cells were maintained in supplemented Roswell Park Memorial Institute (RPMI)
1,640 medium (Mediatech, Inc., Herndon, VA) supplemented with 10% (v/v) heat inactivated
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fetal bovine serum (FBS) (Hyclone, Inc., Logan, UT), 0.3% (w/v) L-glutamine, 1% (v/v)
penicillin/streptomycin (BioWhittaker, Walkersville, MD) and 10 µg/mL insulin (Sigma, St
Louis, MO); SKBR3 cells were maintained in supplemented Improved Modified Eagle
medium (IMEM) Zn2+ option (Invitrogen) supplemented with 10% FBS and 1%
penicillin/streptomycin; and 184A1 cells were maintained in DMEM/Ham's F-12 (1:1)
medium supplemented with 5% (v/v) horse serum (Invitrogen), 20 ng/mL rhEGF (Promega
Corp, Madison, WI), 10 µg/mL insulin and 0.5 µg/mL hydrocortisone (Sigma). All cell lines
were cultured in a humidified incubator at 37°C and 5% (v/v) CO2. As similarly described in
Kulkarni et al. (2012), serum-free media conditioned by an equal number of cells from each
of the three cell lines were collected following a wash sequence in serum-free media (0 h
sample) and after 48 h. The secretome was enriched in the conditioned media using a
staged centrifugation protocol, as described in Kulkarni et al. (2012), and cleaned-up using
a 2D clean-up kit from GE Healthcare (Cat. 80-6484-51).

2.2.3 Functional Annotation
Functional annotation of the identified proteins was performed using a variety of data
integration sources. GeneMANIA was used to query curated protein–protein interaction data
sources and infer interaction networks and likely unobserved nodes based upon the
observed protein data set (www.genemania.org Mostafavi et al., 2008). Using the default
network weighting method, protein–protein interactions were identified based upon
experimental evidence of protein–protein interactions in Homo sapiens (61 curated
references) and predicted protein-protein interactions based upon homology with other
species (50 curated references). The unobserved nodes were pruned from the network that
were based solely on predicted interaction and had one edge. The remaining nodes were
arranged based upon their subcellular location, as annotated in the UniProt Protein
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Knowledgebase (www.uniprot.org), and color-coded based on association with human
exosomes as cataloged in the ExoCarta database (www.exocarta.org Mathivanan et al.,
2012). Pathway enrichment was determined using DAVID Bioinformatics Resources 6.7
(david.abcc.ncifcrf.gov Huang et al., 2009a,b) and Ingenuity Pathway knowledgebase
(www.ingenuity.com), as described in Kulkarni et al. (2010). Briefly, the significance of
enriched pathway within the identified protein data set was determined by a right-tailed
Fisher's Exact test of a 2 × 2 contingency table with the Benjamini-Hochberg correction for
multiple hypothesis testing. The likelihood is calculated based on the number of identified
proteins mapped to the pathway relative to the total number of proteins in the pathway and
the total number of identified proteins relative to the total number of proteins associated with
any pathway in the database. The null hypothesis tested was that the functional annotations
associated with the observed proteins were likely to be observed by random chance alone.
A P-value of less than 0.05 was considered statistically significant and suggests that the
functional annotation was not observed by random chance alone. In using a Fisher's Exact
test for pathway enrichment, we assume that observing a protein in a secretome sample
was a binary result, where the abundance of an observed protein was considered to be
above minimum threshold and subsequent differences in abundance were not explicitly
considered. This interpretation is consistent with the qualitative nature of our proteomic
workflow.

2.2.4 Scanning Electron Microscopy
As an external validation of the proteomic results, putative exosomes were isolated
from conditioned media by differential centrifugation as follows: 300 g for 10 min to remove
cells, 2,600 g for 10 min to remove residual cells and debris, 10,000 g for 60 min to remove
microparticles, and 100,000 g for 2 h to collect exosomes in pellets. Centrifugation steps

- 57 -

were performed using a Beckman Coulter X-14R centrifuge and a Beckman Coulter XL90
ultracentrifuge with proper rotors, open-top (Cat#: 355631) or capped (Cat#: 355618, Cat#:
355655) thickwall polycarbonate tubes (Beckman Coulter). Once isolated, the putative
exosomes were resuspended in 0.2–1 mL DPBS. A solution containing the secretome
isolate was dipped over clean silicon chips and liquid was evaporated after 15–60 min at
room temperature. Silicon chips were mounted on SEM stage by carbon paste. To make
surface conductive, a 2–5 nm thick coating of gold-palladium was applied by sputtering (SPIModule Sputtering, Argon as gas for plasma) before imaging by scanning electron
microscopy (SEM Hitachi S-4700). SEM was done under low beam energies (5.0 kV).
Analysis of exosome sizes were done using the SEM images via ImageJ and the density
distribution of exosome diameters were obtained using R/Bioconductor Version 2.14.1.

2.3 RESULTS
2.3.1 Secretomes of BT474 and SKBR3 Cell Lines Contain Many Shared Proteins But
Are Different From 184A1 Secretome
Proteins were concentrated from media conditioned by these three cell lines for 48 h
and separated using two-dimensional gel electrophoresis, as shown in Figure 2.1.
Conditioned media used in the final wash step was used to establish a protein background
(0 h sample) for the BT474 and SKBR3 secretomes. In the 0 h samples, 20 spots were
picked from both lines of which 12 were identified in the SKBR3 sample and 10 were
identified in the BT474 sample. In the 48 hr samples, 91 gel spots were selected for
identification from the SKBR3 cell line and 96 gel spots were selected in the BT474 cell line.
Of the selected spots in 48 h sample, 54 BT474 proteins, and 63 SKBR3 proteins were
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identified, which corresponded to an overall likelihood of success in protein identification of
63%. Approximately 90% of the identified spots had sequence coverage 25% or greater.

Figure 2.1. 2-D gel electrophoresis maps of secretomes from SKBR3 and BT474 cell
lines are similar but distinct from 184A1 cell line. Representative results from
concentrated media conditioned with SKBR3 (Panel A - 48 hour sample), BT474
(Panel B - 48 hour sample), and 184A1 (Panel C - 48 hour sample) cell lines. The
horizontal axis corresponds to isoelectric focusing using a 7 cm IPG strip with pH
range 4–7. The vertical axis corresponds to molecular weight separation using a 12%
SDS-polyacrylamide gel with resolution between 10 to 250 kDa, as indicated by the
molecular weight standard shown in panel A. Results representative of three
biological replicates for SKBR3 and BT474 and two technical replicates for 184A1
cell.

As an independent validation test, the predicted molecular weights of the proteins
identified in the SKBR3 and BT474 secretomes showed good agreement with the observed
molecular weights (see Fig. 2.2). As expected, theoretical versus observed pI exhibited
greater uncertainty, as post-translational modifications of proteins tends to shift the pI rather
than the molecular weight of proteins. These post-translational modifications may be
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attributed to cellular differences or introduced by the 2DE protocol. For instance, protein
phosphorylation typically increases the acidity resulting in a shift in the isoelectric focusing
point. Similarly, carbamylation of cysteine and oxidation of methionine are two examples of
protein modifications that are a result of iodoacetamide and urea in the lysis buffer and that
can shift the observed pI. As an additional validation, the presence of 78 kDa glucoseregulated protein (HSPA5), Ezrin, and Interleukin enhancer-binding factor 2 (ILF2) in the
BT474 and SKBR3 secretomes were confirmed by Western blot (see Panel D in Fig. 2.2).
HSPA5 was identified in both BT474 (spot 77) and SKBR3 (spot 57) secretomes and was
present in the 48 h but not in the 0 h BT474 samples. This suggests that HSPA5
accumulates in cell-conditioned media. In comparing the two cell lines, HSP5A appeared to
be greater in the SKBR3 than the BT474 secretome, where GAPDH was used to normalize
loadings. As we will discuss later, GAPDH is also an exosome-associated protein. Ezrin and
ILF2 were initially selected as they were identified in only the SKBR3 and BT474
secretomes, respectively. However, Western blot results suggest that they are present in
both secretomes but have different relative abundance, which is also supported by the 2DE
secretome maps. ILF2 was identified in the BT474 secretome in spot 44. In the 2DE results
for the SKBR3 secretome, spot 43 is the corresponding spot but was not able to be identified
independently. Ezrin was identified in the SKBR3 secretome in spot 86, while the
corresponding spot in the BT474 secretome map, spot 71, was also not identified
independently. Collectively, the Western blot results confirm the MALDI-TOF MS protein
identification results.
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Figure 2.2. Validation of MALDI-TOF MS identification of secretome proteins. The
theoretical molecular weights of identified proteins in 48 hour SKBR3 (Panel A),
BT474 (Panel B), and 184A1 (Panel C) secretomes were compared against observed
molecular weights, which were estimated based upon molecular weight standards.
For SKBR3 and BT474 proteins, this comparison is an independent validation test.
For 184A1 proteins, molecular weight information was used to help identify proteins,
as the Aldente algorithm for peptide mass fingerprinting was no longer available. The
presence of three identified proteins were also confirmed by Western blot (Panel D).
The 78 kDa glucose-related protein (HPSA5) and Interleukin enhancer-binding factor
2 (ILF2) were confirmed by Western blot to accumulate in BT474-conditioned media
(0 h versus 48 h samples - upper left). Using GAPDH as a loading control, HSP5A
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appeared to be greater in the SKBR3 secretome (lower left), while ILF2 (upper right)
and Ezrin (lower right) were present in both BT474 and SKBR3 secretomes.

Of the identified proteins, the BT474 secretome contained 43 unique proteins that
did not overlap with the 0 h sample, as summarized in Table 2.1. Similarly, 41 unique
proteins were identified in the SKBR3 secretome. As mirrored by the similarity in 2-D
secretome maps, almost 50% of the identified proteins were common to both the BT474
and SKBR3 secretomes. In comparison, 84 gel spots were picked for identification from the
184A1 secretome collected at 48 h. Of the 184A1 samples, 49 unique proteins were
identified. Among the three 48 h secretomes, only proteasome activator complex proteins
(PSME1/PSME2) were observed in all three, while only transferrin receptor protein 1
(TFRC) was shared between 184A1 and SKBR3 secretomes and only Serpin B6
(SERPINB6) was shared between 184A1 and BT474 secretomes. While culturing these
three cell lines in the absence of serum may be a confounding factor, we did not see
significant differences in viability during the 2 day experiment. Given the similarity between
the BT474 and SKBR3 secretomes, these two sets of unique secretome proteins were used
for subsequent functional annotation in the form of protein interaction network inference and
pathway enrichment.
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Table 2.1 Proteins identified in SKBR3 and BT474 secretomes
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2.3.2. BT474 and SKBR3 Cell Lines Both Secrete Exosomes
To glean insight into the functional roles of these secreted proteins, GeneMANIA was used
to develop a network based upon protein–protein interactions among the identified proteins.
We analyzed the secretomes derived from the BT474 and SKBR3 cell lines separately and
also the combined data set (see Fig. 2.3), given that half of the proteins were observed in
common. The resulting protein–protein interaction networks include both the identified
proteins and proteins that are inferred based upon known interaction with the set of
observed proteins. Using the resulting protein–protein interaction network as a starting point,
we also rearranged the networks to reflect the subcellular location of the proteins.
Interestingly, the majority of the identified proteins have been reported to reside in the
cytoplasm. Very few proteins were associated with the extracellular space or the plasma
membrane. The sparse association with the plasma membrane was expected as proteins
in the plasma membrane should be lipophilic and the insolubility of lipophilic proteins limits
isoelectric focusing on immobilized pH gradients (Reisinger and Eichacker, 2008). While our
secretome enrichment protocol is designed to exclude cellular debris, the cytosolic proteins
could reside in a number of membrane vesicles that are released by cells. These vesicles
include microvesicles that are released by the outward blebbing of the cell membrane,
apoptotic vesicles that are released during programmed cell death, and exosomes that
originate within intracellular multivesicular compartments and are constitutively released by
cells through exocytosis (van der Pol et al., 2012). We felt that apoptotic vesicles were
unlikely to be a major contributor to the observed secretome as we did not observe
significant differences in viability during the 48 h that the cells conditioned the media. Given
the recent interest in exosomes as a new mode of cell-to-cell communication, we used the
ExoCarta database to annotate the nodes within network based upon previous reports that
a particular protein has been observed in exosomes. Of the identified proteins, 28 of 41

- 64 -

proteins in SKBR3 and 26 of 43 proteins in BT474 secretomes had been observed in human
exosomes. While not identified in the proteomic analysis but observed by Western blot,
GAPDH is also associated with exosomes. In comparison to the SKBR3 and BT474 cell
lines, a lower proportion of the proteins identified in the 184A1 secretome have been
associated with exosomes (i.e., 20 of 49). Based upon the list of proteins currently
associated with human exosomes relative to the total number of identifiable proteins, the
functional annotation that many of these proteins are associated with exosomes was
significant for all three secretomes (Fisher's Exact Test: P-value <1e−10).
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Figure 2.3. SKBR3 and BT474 Proteins are Secreted by Exosomes. Protein-protein
interaction networks suggest that the majority of proteins identified in both SKBR3
and BT474-conditioned media are derived from exosomes.

Protein-protein

interaction networks were constructed in GeneMania using the union set of all
identified proteins in SKBR3 and BT474 secretomes (Panel A), using just the SKBR3
secretome, and using just the BT474 secretome. The proteins were arranged based
upon similarity in subcellular location. Gray circles indicate identified proteins while
white circles indicate proteins inferred based upon known interactions with identified
proteins. The blue edges indicate experimentally observed protein-protein

- 66 -

interactions in Homo Sapiens, while brown edges are predicted protein-protein
interactions based on homology with other species. Encircled nodes are found in the
Exocarta database, which suggests that they are associated with exosomes. Nodes
encircled in blue are from SKBR3, in yellow from BT474, and in green are common
between SKBR4 and BT474. The nodes encircled in red are inferred only in the
amalgamated network and are associated with exosomes. Scanning electron
microscopy was used to confirm that the secretome contained membrane vesicles
(Panel B - SKBR3-conditioned media). The size and distribution of membrane
vesicles were consistent with exosomes (Panel C). SEM results representative of a
least two replicates.

To validate this functional annotation, we isolated secreted vesicles from media
conditioned for 48 h by SKBR3 cells using a staged centrifugation approach. We imaged
the resulting isolated fraction using scanning electron microscopy (SEM). As shown in
Figure 2.3B, the isolated fraction was rich in nanoscale vesicles. While there is no
consensus on nomenclature, the different vesicles can in part be distinguished based upon
their morphology. Exosomes are around 100 nm in diameter and exhibit a uniform
distribution in size. In contrast, microvesicles and apoptotic vesicles exhibit heterogeneous
distributions that range in size from 50 to 4,000 nm in diameter. Using image segmentation,
we determined that the vesicles exhibited morphology consistent with exosomes, as they
were uniformly distributed with a mean diameter of 183 nm (n = 223, s.d. ± 35 nm) (see Fig.
2.3C). While the average size may seem slightly larger than the reported range of
exosomes, the SEM images were obtained using freshly isolated exosomes. If exosomes
are stored in PBS at 4°C, their size is reduced by 50% within 7 days (Sokolova et al., 2011).
Of the identified proteins, GDI2 and RAB37 provide support that these nanoscaled vesicles
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are of endosomal origin as these proteins play key roles in delivering intracellular cargo for
exocytosis (Masuda et al., 2000; Ullrich et al., 1993). RAB37 is a GTPase that along with
RAB3, RAB26, and RAB27A/B regulate the transport of secretory vesicle and granules
(Stenmark, 2009). While their specific roles for exosome transport and release remains
unclear, knock-down of RAB27A inhibits exosome production (Peinado et al., 2012) but not
the release of secreted proteins (Bobrie et al., 2012). Moreover, the broad field of view in
the SEM image provided better evidence of the size distribution than is typically presented
(e.g., Peinado et al., 2012; Sokolova et al., 2011).

2.3.3. Functional Annotation of the Secretome Suggests That BT474 and SKBR3
Exosomes Transport Metabolic Enzymes and Present MHC Class I Antigens
Finally, we wanted to determine which pathways would be impacted by the transfer
of exosomal proteins between cells. Using DAVID, we identified a set of common gene
ontology terms that were shared across the BT474 and SKBR3 secretomes. As shown in
Figure 2.4A, these common gene ontology terms were grouped into antigen-processing and
presentation pathways or metabolic pathways. In terms of enriched canonical pathways,
identified proteins in both breast cancer secretomes were associated with antigenprocessing and presentation via the major histocompatibility class I (see Fig. 2.4B) and
glycolysis/gluconeogenesis (see Fig. 2.4C). In contrast, no canonical pathways were
identified as significantly enriched in the list of proteins identified in the 184A1 secretome.
However, two 184A1 secretome proteins, HLA-B and PSME1, are associated with antigenprocessing and presentation. While these pathway enrichment results were obtained using
uncurated sources, we also observed similar pathway enrichment using Ingenuity Pathway
Analysis (IPA), a curated source of data. IPA results suggested that, of the top 10 canonical
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pathways for each cell line, seven were common between the BT474 and SKBR3
secretomes.

Figure 2.4. BT474 and SKBR3 Exosomes may be Involved in Antigen Presentation
and Metabolism. Pathway enrichment suggests that the exosomes derived from both
BT474 and SKBR3 cells play similar functional roles in presenting antigens and
modulating metabolism.

Functional annotation of the identified proteins using

enrichment of biological pathways and gene ontology (GO) terms in DAVID (Panel A:
TOP - antigen presentation cluster, BOTTOM - metabolism cluster). Green block
indicated that a particular gene (columns) that is associated with a given pathway/GO
term (rows) was identified in the secretome (BT-474 - red, SKBR3 - black, both cell
lines - blue). Black regions of the grid indicate that GO association for a gene has not
been reported. Graphical summaries of the MHC class I pathway (Panel B) and the
glycolysis/gluconeogenesis pathway (Panel C) obtained from the KEGG Pathway
database were annotated with the identified proteins (BT-474 secretome - red star,
SKBR3 secretome - black star, secretomes from both cell lines - blue star).
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2.4 DISCUSSION
A common application of proteomics for secretome analysis is to discover
biomarkers associated with different molecular subtypes of cancer (e.g., Kulasingam and
Diamandis, 2007; Makawita et al., 2011; Pavlou et al., 2013; Sepiashvili et al., 2012;
Srirajaskanthan et al., 2010; Wu et al., 2010; Xue et al., 2008). Here, we aimed to identify
differences in how malignant cells associated with a particular molecular subtype of breast
cancer condition their environment differently from normal cells derived from the same tissue
using a proteomics approach. Collectively, the secretome analysis of in vitro cultured BT474
and SKBR3, two HER2+ breast cancer cell lines, versus 184A1, a normal human mammary
epithelial cell line, suggests that exosomes are a major mode by which these cancer cells
condition the tumor microenvironment. The 50% overlap in the proteins identified in the
BT474 and SKBR3 secretomes was particularly intriguing as this overlap was not observed
in our recent proteomic analysis of whole cell lysates derived from these cell lines (Kulkarni
and Klinke, 2012). In comparison, only three of the 41 SKBR3 and only four of the 43 BT474
secretome proteins are common with the observed whole cell proteome. In addition, the
presence of exosomes presents challenges for separating the proteins present in the
secretome by 2DE due to the increase in membrane surface area and associated lipids.
Lipids present within an unfractionated secretome sample may limit the effectiveness of
detergents in solubilizing proteins. As the goal of this study was to observe as many proteins
as possible in the secretomes using the same proteomics workflow as our whole cell lysate
study rather than to quantify differences in abundance, the results may be viewed as
qualitative. An alternative approach is Stable Isotope Labeling by Amino Acids in Cell
Culture (SILAC) (Ong et al., 2002, 2003; Schulze and Mann, 2004), where isotope-labeled
amino acids, specifically arginine, and lysine, are replaced in the culture media of the tumor
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cells for at least five population doublings prior to collecting secretome. The entire proteome
of the tumor cells then incorporates SILAC encoding and newly secreted proteins contain
isotope labeling. A SILAC approach improves the detection of secreted proteins from
contaminating proteins like keratins and serum derived factors (Henningsen et al., 2010).
Despite these caveats, the protein identification, Western blot, functional annotation, and
SEM results are all consistent in suggesting that exosomes are a major mode of cell-to-cell
communication. While the study of extracellular microvesicles is an area of intense interest,
one of the challenges with placing our findings into biological context is that the exosome
literature is controversial due to inconsistent nomenclature and isolation methods (Raposo
and Stoorvogel, 2013; Simpson and Mathivanan, 2012). Overall our approach was designed
to overcome common criticisms, as we used a differential centrifugation protocol coupled
with SEM to characterize the size distribution and morphology of fresh samples.
As an emerging mode of cell-to-cell communication, exosomes have been reported
to transfer proteins (van der Pol et al., 2012) and RNA (Ratajczak et al., 2006; Valadi et al.,
2007) between cells. While exosomes are ubiquitously expressed, malignant cells derived
from melanoma and ovarian cancer have been shown to secrete higher levels of exosomes
as compared to normal controls (Logozzi et al., 2009; Taylor and Gercel-Taylor, 2008;
Zhang et al., 2012) that may be attributed to p53-mediated stress response (Yu et al., 2006).
Here the functional annotation of the identified proteins suggests that these exosomes play
a role in antigen presentation. Conventionally, two different cell types enforce cell-mediated
cytotoxic immunity: cytotoxic T lymphocytes (CTLs) and Natural Killer (NK) cells. CTLs kill
tumor cells that express sufficient cognate antigens in the form of a peptide-MHC class I
complex. At the other extreme, NK cells direct cytotoxic activity against cells that do not
express sufficient MHC class I. In contrast to dendritic cell-derived exosomes (Thery et al.,
2001), the significant enrichment of proteins associated with antigen-processing and

- 71 -

presentation via MHC class I molecules in tumor-derived exosomes suggests a possible
decoy strategy whereby tumor antigens are distributed to other cells within the tumor
microenvironment. Alternatively, exosomes may provide a mechanism for these malignant
cells to shed MHC class I molecules as others have shown that HER2 overexpression
downregulates MHC class I expression (Herrmann et al., 2004; Maruyama et al., 2010). As
the tumor antigen epitopes presented by these two human breast cancer cell lines are
unknown, it is difficult to assess directly how peptide-MHC class I complexes on BT474- or
SKBR3-derived exosomes alter the ability of these two cell-mediated immune mechanisms
to control tumor cell growth. One limitation of the study is that all three cell lines are derived
from different individuals and that the observed differences may reflect natural genetic
variation among an outbred population rather than oncogenesis. Although the similarities
between the BT474 and SKBR3 secretomes and their collective difference from 184A1
secretome argue against that possibility, additional studies using syngeneic cell lines may
be informative.
Pathway enrichment also suggests that exosomes may alter the metabolic flux
within surrounding cells through the intercellular transport of metabolic enzymes associated
with glycolysis. The presence of glycolytic enzymes is not unexpected as reprogramming of
energy metabolism is an emerging hallmark of cancer (Hanahan and Weinberg, 2011).
Cancer cells obtain their energy through glycolysis despite the presence of oxygen, a
phenomenon called the “Warburg effect” (Hsu and Sabatini, 2008; van der Heiden et al.,
2009; Warburg, 1956). However, transporting enzymes between cells to alter metabolic flux
through entire pathways using exosomes is intriguing. In addition to altered intracellular
metabolism, malignant cells also elicit a field effect on the surrounding cells by altering the
metabolic environment (e.g., Yakoub et al., 2010). This field effect is observed outside of a
direct cell-to-cell contact region. In development, spatial gradients of secreted proteins,
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called morphogens, shape cell fate (Shvartsman, 2005). Given a constitutive source, spatial
gradients of morphogens are regulated by the rate of consumption of the secreted protein,
through receptor-mediated degradation or extracellular proteolytic degradation, and the
diffusivity of a secreted protein within the tissue matrix (Kicheva et al., 2007). Following from
reaction versus diffusion considerations in porous media embodied by the Thiele modulus
(Goentoro et al., 2006; Thiele, 1939; Thurber et al., 2007), secreted proteins with low
diffusivity promote while secreted proteins with high diffusivity inhibit the formation of spatial
gradients. In addition, the diffusivity of a secreted protein within a porous matrix is dependent
on the affinity of the protein for the porous matrix and the size of the secreted protein (Haller
and Saltzman, 1998). Compared to oxygen, glucose and other metabolic substrates, these
transport considerations imply that exosomes may contribute to field effects due to their
relatively large size and potential to transport metabolic enzymes. Cells that enter the tumor
microenvironment may then be forced to up regulate glycolytic metabolism, which may have
a detrimental effect on the function of tumor-infiltrating cytotoxic T lymphocytes (Sukumar
et al., 2013). Moreover, GAPDH, which we observed by Western blot, expressed in excess
enables this glycolytic enzyme to bind to the 3′ untranslated region of the Interferon gamma
(IFNγ) mRNA to inhibit its expression instead of glyceraldehyde-3-phosphate, its normal
metabolic substrate (Chang et al., 2013). IFNγ is a cytokine produced by T lymphocytes that
increases the expression of MHC class I complexes on the surface of cells. Collectively, the
proteomic analysis of the secretome of two HER2+ breast cancer cell lines compared with
a normal human mammary epithelial cell line suggest that tumor-derived exosomes
contribute to two of the emerging hallmarks of cancer: evading tumor immunosurveillance
and deregulating cellular energetics.
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CHAPTER 3: MELANOMA EXOSOMES IMPACT CYTOTOXIC T LYMPHOCYTE
TRANSCRIPTOMES AND MITOCHONDRIAL RESPIRATION

While recent clinical studies demonstrate the promise of cancer immunotherapy, a
barrier for broadening the clinical benefit is identifying how tumors locally suppress
cytotoxic immunity. As an emerging mode of intercellular communication, exosomes
secreted by malignant cells can deliver a complex payload of coding and non-coding RNA
to cells within the tumor microenvironment. Here, we quantified the RNA payload within
tumor-derived exosomes and the resulting dynamic transcriptomic response to cytotoxic
T cells upon exosome delivery to better understand how tumor-derived exosomes can
alter immune cell function. Exosomes derived from B16F0 melanoma cells were enriched
for a subset of coding and non-coding RNAs that did not reflect the abundance in the
parental cell. Upon exosome delivery, RNAseq revealed the dynamic changes in the
transcriptome of CTLL2 cytotoxic T cells. In analyzing transiently co-expressed gene
clusters, pathway enrichment suggested that the B16F0 exosomal payload altered
mitochondrial respiration, which was confirmed independently, and upregulated genes
associated with the Notch signaling pathway. Interestingly, exosomal miRNA appeared to
have no systematic effect on downregulating target mRNA levels.
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3.1.

INTRODUCTION
Cancer immunosurveillance is the process by which the host's immune system

recognizes and eradicates nascent neoplastic cells, limiting cancer development.
However, in some cases, transformed cells are not completely eliminated and tumor
escape can occur after a dynamic equilibrium with immune cells. In this process, new
tumor cell variants are selected due to their loss of immunogenicity and their increased
ability to suppress anti-tumor immune effectors (Vesely 2011). Cancer cells can actively
induce T cell dysfunction through several mechanisms that involve conditioning the tumor
microenvironment via soluble cues. Myeloid-derived suppressor cells (MDSC), tumorassociated macrophages (TAM), tumor-associated neutrophils (TAN) and regulatory T
cells (Tregs) are expanded by tumor-derived soluble cues and inhibit anti-tumor T cell
responses (Rodriguez 2004, Fridlender 2009, Gabrilovich 2012, Ugel 2015, Joshi 2015,
Tanaka 2017). MDSC, TAM and TAN contribute to T cell dysfunction by expressing
arginase 1 that can deplete L-arginine and MDSC limit L-cysteine availability, which are
both essential amino acids for the proliferation of T cells (Rodriguez 2004, Fridlender
2009, Srivastava 2010). MDSC-mediated production of reactive oxygen and nitrogen
species, through NADPH oxidase and inducible nitric oxide synthase (iNOS), impairs
antigen recognition, activation and function of T cells (Corzo 2009, Nagaraj 2010).
Additionally, immunosuppressive molecules like IL-10, TGFb, extracellular adenosine and
prostaglandin E2 are preferentially released by Tregs and TAM, whereas IL-12 and TNF
production by TAM and TAN, respectively, are significantly reduced (Torroella-Kouri 2009,
Fridlender 2009, Tanaka 2017, Ugel 2015}. Other studies demonstrate that hypoxic
conditions and the predominant metabolic pathways in cancer cells generate an acidic
tumor microenvironment and deprive T cells of essential metabolites like glucose, both
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mechanisms associated with the impairment of T cell survival and effector functions
(Calcinotto 2012, Bellone 2013, Chang 2015).
Cell-to-cell communication is important in understanding the dynamic interaction
between tumor and immune cells in the tumor microenvironment. In contrast to the soluble
cues that condition the tumor microenvironment, exosomes are emerging as an important
mode of intercellular communication. These nanoscaled extracellular vesicles are actively
released by cells to transfer proteins, mRNA, and non-coding RNAs between cells.
Interestingly, tumor cells release exosomes at a greater rate than normal cells, which
suggests that they may play an important role in cancer (Jenjaroenpun 2013). Some of
the earliest exosome studies suggest that exosomes mediate B cell transformations
(Raposo 1996, Zitvogel1998). Subsequent studies reinforce the notion of exosomes as
immunoregulatory modulators and illustrate the ways in which tumor exosomes are
capable of altering their microenvironment. Proteomic analysis suggests that exosomes
from human breast cancer cell lines and not from normal human mammary cells are
enriched in proteins involved in glycolytic metabolism (Klinke 2014). Melanoma exosomes
promote

metastasis

by

delivering

a

payload

that

upregulates

oncoproteins

(Peinado2012). In mouse melanoma cell models, exosomes from B16F0 but not
Cloudman S-91 or Melan-A cells inhibit cytotoxic T cell proliferation and are enriched for
mRNA transcripts that target immune pathways, such as Ptpn11 and Dnmt3a (Wu2016).
While many prior studies focus on characterizing exosomal payloads or systemic
response at a single point in time to exosomal delivery, a systematic analysis of how gene
expression changes with time in response to delivery of an exosomal payload to a target
cell remains unclear. To better understand how exosomes can regulate anti-tumor
immunity, the goal of this study was to evaluate how the transcriptional landscape in
cytotoxic T cells is changed with time following the delivery of a exosomal payload from
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tumor cells using a mouse melanoma model. In short, the transcriptional landscape
reflected the delivery of an exosomal mRNA payload while exosomal miRNA appeared to
have no effect on transcript abundance. In addition, exosomal payload elicited a dynamic
non-linear response associated with a number of pathways, which was supported by
results from a mitochondrial function assay.

3.2 RESULTS AND DISCUSSION
3.2.1. B16F0 Exosomes Contain mRNA and miRNA
Extracellular vesicles were isolated using a staged centrifugation protocol from
serum-free media conditioned by B16F0 cells. These extracellular vesicles were then
characterized in terms of morphology using scanning electron microscopy and protein
biomarker context (Fig. 3.1). Fresh extracellular vesicles exhibited a round morphology
with a Feret diameter of 166±15 nm (n = 26), which is consistent with prior studies of fresh
exosomes (Wu 2015, Wu 2016). Probing for protein biomarkers associated with
exosomes, we found that samples containing extracellular vesicles were positive for
Hsp70, CD63, and CD9 and negative for CD81, b-actin and b-tubulin. Compared to B16F0
whole cell lysates, Hsp70 and CD63 were present in both samples while the remainder
were not. The absence of CD81 and enrichment of CD9 in the extracellular vesicle
samples has been previously reported for B16F0 exosomes (Wu 2016). The absence of
b-actin and b-tubulin suggested that the extracellular vesicle sample does not contain cell
fragments, such as vesicles released during cell death. These exosomes were also able
to deliver GFP synthesized by B16F0 cells to CTLL2 cells (Fig. 3.1C). GFP was initially
observed as bright punctae both in the media and within CTLL2 cells that became more
dispersed with time within the CTLL2 cells. Functionally, 48 hour treatment with 0.2 mg/mL
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of B16F0 exosomes had no impact on the proliferation or viability of CTLL2 cells (data not
shown). Collectively, the results suggest that the extracellular vesicles isolated from the
B16F0 cell-conditioned media are exosomes and that these exosomes can deliver a
biological payload to CTLL2 cells.
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Figure 3.1. B16F0 Produce Exosomes. B16F0 release extracellular vesicles with
uniform morphology that contain proteins commonly associated with exosomes that
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can deliver a biological payload to CTLL2 cells. (A) A SEM picture of extracellular
vesicles isolated by ultracentrifugation of media conditioned for 24 hours by B16F0
cells (bar indicates 200 nm). (B) Western blot analysis of B16F0 whole cell lysates
(WCL) and extracellular vesicles (EXO) for proteins commonly associated with
exosomes, where 20 µg of protein was loaded in each lane. (C) B16F0 cells were
transfected with a lentivirus-based XPack-GFP plasmid that targets GFP to
exosomes. Untreated CTLL2 cells and CTLL2 co-cultured with exosomes isolated
from B16F0-XPgfp cells for either 3 or 24 hours and imaged by fluorescence
microscopy. After 24 hours, CTLL2 cells treated with B16F0-XPgfp exosomes were
washed three times with DPBS and also imaged by fluorescence microscopy. Phase
contrast and merged images are shown for comparison. The fluorescence intensity
in GFP images has been colored using a black-yellow-blue color scale. Scale bar
indicates 50 µM.

As exosomes can carry a complex payload of coding and non-coding RNA, we
next characterized the RNA payload within B16F0 exosomes compared to the parental
cells. A Bioanalyzer was first used to characterize the overall RNA quality (Fig. 3.2A).
Bioanalyzer results comparing RNA in the parental cells versus exosome samples
suggested that exosomes appear to contain full-length mRNA transcripts in addition to
smaller miRNA fragments while ribosomal RNAs dominate the signature derived from the
parental cells. The broad distribution of RNAs between the characteristic 5S and 18S
ribosomal RNA peaks indicated that much of the content of the RNAs are between 120 to
1869 nucleotides long. The presence of characteristic 5S, 18S, and 28S rRNA peaks
within the exosome samples was likely residual cellular debris attached to the outside of
the exosomes as washing the exosome samples in PBS prior to analysis reduced these
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ribosomal RNA peaks (see Fig. 3.3A in Wu 2016). Affymetrix microarrays were then used
to quantify mRNA and miRNA within the exosome samples compared to parental B16F0
cells. Following isolation of mRNA from exosome and whole cell samples, exon-level
mRNA microarrays were used to quantify the relative abundance of transcripts (see Fig.
3.3 in (Wu 2016)). Similarly, the exosomal miRNA payload was characterized using an
Affymetrix GeneChip miRNA 2.0 microarray (see Fig. 3.2). A Welch t-test was used to
identify miRNAs that were present above background, where a cut-off p-value of 0.05 was
used.

Figure 3.2. B16F0 Exosomes Contain Unique miRNAs. B16F0 exosomes contain
miRNAs that are differentially packaged into exosomes relative to parental cells. (A)
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The distribution of RNA isolated from parental B16F0 cells (top panel) and B16F0
exosomes (bottom panel) was quantified using microfluidic electrophoresis. (B) The
overall distribution in exosome versus cellular abundance of miRNAs (gray curve)
was deconvoluted into three normally distributed populations: miRNAs enriched in
cells (blue curve - 40% of total), miRNAs equally distributed between cell and
exosomes (black curve - 30% of total), and miRNAs enriched in exosomes (red curve
- 30% of total). (C) A Venn diagram summarizes the number of miRNAs that are
present above background and are differentially expressed between cell and
exosome samples. (D) Hierarchical clustering of miRNA detected above background
(Welch t-test p-value<0.05) from four B16F0 exosomes and four B16F0 cell samples
using Affymetrix miRNA microarrays.

Similar to the distribution of mRNA between exosomes and parental cells, the
distribution of miRNAs between exosomes and parental cells exhibited one of three
different phenotypes: selectively enriched in exosomes, equally distributed between
exosomes and parental cells, and more abundant in parental cells. To identify the fraction
of the total number of miRNAs that are associated with each of these three phenotypes,
we deconvoluted the cumulative distribution into three different subsets (Fig. 3.2B). Of the
miRNAs present above background in either the exosome or parental cell samples, 30%
of the miRNAs were more abundant in the exosomes, whereas 40% were more abundant
in the samples obtained from the parental B16F0 cells. The remaining percentage of
miRNAs were equally distributed between parental cell and exosomes, accounting for the
last 30% of total recorded miRNA transcripts. A Venn diagram also summarizes the
number of miRNAs detected above background, where 30 miRNAs were only detected in
exosome samples, 139 miRNAs were only detected in parental cell samples, and 124
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miRNAs were detected in both samples. Of all miRNAs detected above background, 96
were more abundant in the exosome samples and 197 miRNAs were either equally or
more abundant in parental cell samples.
A heatmap visualized clustering between the samples and the miRNAs (Fig.
3.2D). Within this heatmap, clear division in the pattern of miRNA expression is evident
between the samples such that all of the replicates cluster together. The abundance of
miRNAs among the samples clusters similarly as the distributions shown in panel B. A
cluster at the top of the heatmap represents those miRNAs that are equally distributed
between parental cell and exosomes, a cluster in the middle of the heatmap represents
those miRNAs with low abundance in the exosomes but higher abundance in the cell
samples, a cluster at the bottom of the heatmap represents those miRNAs with high
abundance in the exosomes and low abundance in the cell samples with a small set of
miRNAs that are highly enriched in exosomes and nearly absent in the parental cells. This
most highly enriched group included miRNAs: mmu-miR-711, mmu-miR-1187, and
members of the miR-466 family (mmu-miR-466j, mmu-miR-466f-5p, mmu-miR-466f-3p,
mmu-miR-466f, mmu-miR-466g, mmu-miR-466c-5p, and mmu-miR-466i-3p). While these
miRNAs exhibited high exosomal enrichment, they were not the most abundant miRNAs
in exosome samples. The twenty most abundant miRNAs and mRNAs found in the B16F0
exosome samples are listed in Table 3.1. Not surprising, the most abundant mRNA in
exosomes was melanoma antigen (Mela). Interestingly, the most abundant miRNA, by a
factor of 2.2 over the second most abundant miRNA, was mmu-miR-709, which has been
reported to activate Wnt/b-catenin signaling by targeting GSK3b (Chen2014). In
comparing the results for probe sets that recognize the precursor hairpin versus mature
miRNA, miRNAs in the exosomes were predominantly mature.
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Table 3.1 Twenty of the most highly abundant miRNAs and mRNAs in B16F0 exosomes

A subset of mRNAs that exhibited differential and similar abundance between
exosome and whole cell samples were subject to semi-qualitative RT-PCR that confirmed
that these transcripts were intact full-length open reading frames (see Fig. 3.4 in Wu 2016)
and subject to quantitative RT-PCR that confirmed the relative abundance predicted by
the microarray results (Fig. 3.3 A). A correlation coefficient of 0.90 between the abundance
ratio observed by microarray compared to that observed by qRT-PCR suggests a strong
positive correlation between these two measurements. Similarly, a subset of miRNAs
present in both exosome and parental cell samples were subject to quantitative RT-PCR
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to confirm the relative abundance predicted by the microarray results (Fig. 3.3B). While
the value was lower than for mRNA, a correlation coefficient of 0.57 still suggests a strong
positive correlation between these two measurements of miRNA differential abundance.
Interestingly, miRNAs in the exosomes overlap in their targeting of specific mRNA
transcripts and are predicted to impact multiple pathways (Fig. 3.4). Two of the top three
most significantly enriched pathways were associated with cell-mediated immunity. These
pathways were the Type I Interferon Pathway and NEF-mediated downregulation of MHC
Class I complex cell surface expression. Targeted transcripts of the Type I Interferon
Pathway included the Janus Kinases JAK1 and TYK2 while transcripts targeted in the
NEF-mediated pathway included multiple components of the adaptor protein complex AP1 (AP1G1, AP1M1, AP1M2, AP1S1, AP1S2). Collectively, the results suggest that B16F0
exosomes contain a payload of both coding and non-coding RNAs whose abundance
does not reflect the abundance in the parental cell and can exert a concerted impact on
the transcriptional landscape in recipient cells.
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Figure 3.3. Relative abundance of mRNA and miRNA between B16F0 exosomes and
cells. Relative abundance of mRNA and miRNA between B16F0 exosomes and cells
were consistent between qRT-PCR and microarray analyses. (A) As reported by Wu
et al. (2016), the abundance of ten transcripts (Kpnb1, Rnf14, Rnd2, Ptp4a3, Ptpn11,
Eif2c2, Hipk2, Eif4ebp2, Dnmt3a, and Wsb2) in B16F0 exosomes versus B16F0 cells
were quantified by quantitative RT-PCR (mean ± SD, n = 3) and compared against the
relative abundance of mRNAs assayed by cDNA microarray. The linear relationship
was quantified by a correlation coefficient of 0.90. (B) The abundance of ten miRNAs
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(miR-181a-5p, miR-31-5p, miR-378a, miR-34b*, miR-720, miR-34c*, miR-1949, let-7d*,
miR-709, and miR-467f) in B16F0 exosomes versus B16F0 cells were quantified by
quantitative RT-PCR (mean ± SD, n = 3) and compared against the relative abundance
of miRNAs assayed by miRNA microarray. The linear relationship was quantified by
a correlation coefficient of 0.57.
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Figure 3.4. Exosomal miRNA overlap in targeting specific mRNA transcripts and
collectively target multiple pathways. (A) The targeting of specific mRNA transcripts
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(yellow nodes) by miRNAs present in B16 exosomes (blue nodes) is summarized by
a multi-dimensionally scaled network diagram. The size of the miRNA nodes were
scaled by relative abundance in exosomes. Nodes with less than two edges were
pruned from the network to improve clarity. (B) Possible pathways targeted by
exosomal miRNAs was determined by enrichment of miRNA to gene to pathway
relationships. Using the miRNApath package, significance of pathway enrichment
relative to random chance was assessed by random permutation where an adjusted
p-value of less than 0.02 was considered significant.

3.2.2. Signature Associated with mRNA but not miRNA Exosomal Payload is
Observed in Cytotoxic T Cell Transcriptome
Given the importance of exosomes as a mode of intercellular communication
and the emerging importance of tumor-derived exosomes in shaping the tumor
microenvironment, we wanted to assess the impact of tumor-derived exosomes on the
transcriptome of cytotoxic T lymphocytes, an important effector cell in controlling tumor
growth. As a model system, we exposed CTLL2 T cells, an immortalized cytotoxic T cell
line, to exosomes derived from B16F0 cells and monitored the transcriptome as a function
of time using RNA sequencing. Specifically, mRNA isolated from the starting population
of CTLL2 cells (0 hr) and from treated and untreated cells at 4 different time points (0.5,
2, 4, and 8 hour) were subject to RNA-Seq analysis. Using three biological replicates for
each experimental condition, samples were randomly assigned to one of two HiSeq1500
batch runs. On average, 25.5 million raw reads (± 5.8 million reads) were generated for
each sample and 22.5 million of these reads (± 4.7 million reads) were mappable to the
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host reference genomes. From the mappable reads, 2.3 million reads (±0.6 million reads)
were aligned to multiple positions in the reference genomes and were excluded. The
resulting uniquely mapped reads, which averaged 19.5 million reads (±4.0 with a range
between 7.5 and 30.0 million reads), were retained for further analysis. In addition to
controlling for batch effects, DESeq2 analysis of the uniquely mapped reads was used to
identify differentially expressed (DE) transcripts (Love 2014), whereby we parsed the
analysis into two comparisons. First, we identified transcripts that changed with time in the
untreated samples. Second, we identified DE transcripts that were changed in exosometreated samples at specific time points. These analyses are summarized in Fig. 3.5.
In untreated cells, the number of DE transcripts relative to the 0 hour sample
generally increased with time (Fig. 3.5A). Even with reducing the p-value from 0.1 to 0.04,
the 8 hour time point had greater than 10 times more DE transcripts than any other time
point. In the exploratory data analysis, a reduced p-value was used so that the 8 hour time
point did not swamp the information contained in the samples obtained at other time
points. As illustrated by the heatmap (Fig. 3.5B), no clear trends emerged in the untreated
cells, while a residual batch effect can be seen in clustering samples. In comparing
exosome-treated to untreated samples at each time point, we also found that the number
of DE transcripts was greatest at the 8 hour time point but by a lower margin than in the
time-course analysis (Fig. 3.5C). Interestingly, there was no overlap in the set of DE
transcripts identified in the time-course analysis versus the set of DE genes in exosometreated samples. In addition, a set of 17 DE transcripts were shared across the 0.5, 2, and
4 hour time points, which corresponded to the majority of DE genes at 2 and 4 hours. DE
genes identified at the 0.5, 2, and 4 hour times points were solely increased in exosometreated samples with no genes exhibited a decrease following exosome treatment. In
analyzing the set of DE genes across exosome-treated samples, samples tended to
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cluster based on time point rather than by batch. Overall, the number of DE genes is
expected to increase with time as re-plating CTLL2 cells or treating with exosomes can
elicit a primary response in gene expression that then propagates through genetic
regulatory networks to elicit secondary changes in gene expression. To explore the
biological significance of the clustering results, we focused on three distinct clusters of DE
genes associated with exosome treatment, which are highlighted to the right of the
heatmap in Fig. 3.5D. Cluster 1 is composed of transcripts that were increased within all
exosome-treated samples. In contrast, transcripts within cluster 2 were upregulated at 8
hours in untreated CTLL2 cells compared to exosome-treated cells while cluster 3 includes
transcripts that are downregulated at 8 hours in untreated samples relative to exosometreated CTLL2 cells.
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Figure 3.5. CTLL2 Cell Transcription Responds to Exosome Treatment. Exosome
treatment initiated a different transcriptomic response in CTLL2 cells compared
with the transcriptomic changes observed as a function of time. Venn diagrams of
the number of differentially expressed transcripts observed at different time points
(A) in untreated CTLL2 cells compared to the 0 hour time point and (C) in exosometreated versus untreated samples at each time point. Using p-values calculated
using the DESeq2 package, a more stringent p-value cutoff was used at the 8 hour
time point (p-value < 0.04 ) compared with the 0.5, 2, and 4 hour time points (p-value
< 0.1). (B and D) Hierarchical clustering of collection of differentially expressed
transcripts detected by RNA sequencing from 28 samples distributed across five
time points (0, 0.5, 2, 4, and 8 hour), two experimental conditions (untreated versus
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exosome treated), and two RNA sequencing batches (B1 and B2). Heatmaps in
panels B and D focus on the differentially expressed transcripts summarized in the
Venn diagrams shown in panels A and C, respectively. Three clusters of dynamic
transcript expression profiles are highlighted on the right margin of panel D. Cluster
1 corresponds to transcripts increased at all time points in exosome-treated
samples. Cluster 2 corresponds to transcripts predominantly upregulated in
untreated cells compared to exosome-treated cells at 8 hours. Cluster 3
corresponds to transcripts predominantly downregulated in untreated cells and
upregulated in exosome-treated cells at 8 hours.

Given that genes associated with cluster 1 seemed to increase in abundance
immediately upon exosome treatment, we compared the change in normalized transcript
counts upon exosome treatment to mRNA abundance in B16 exosome samples assayed
by Affymetrix microarray for genes observed by both of these platforms (Fig. 3.6). The
comparison between the RNA-seq analysis of exosome-treated CTLL2 cells and the
Affymetrix microarray analysis of exosomal mRNA payload revealed a linear trend,
whereby a correlation coefficient of 0.90 suggested a strong positive correlation. This trend
becomes more defined with highly abundant transcripts while low abundant transcripts
seemed to deviate from linearity. Such a trend may be due to observational bias as
microarray data can have a broader dynamic range while sequencing data is biased
towards highly abundant transcripts. Low abundant transcripts that trend towards the
mean may have too low of a frequency to be observed at the stated sequencing depth. To
illustrate the overall trend for individual genes associated with cluster 1, the abundance in
exosome-treated and untreated samples of four of the most highly abundant transcripts
are plotted over time (Fig. 3.6B-E). Noticeable differences can be seen across all time

- 101 -

points when examining all four genes. Greatest differences among all of the plots is visible
at the 0.5 hour time point, indicating these genes are all initially upregulated following the
exosome treatment and remain upregulated at the other time points. We also noted that
not all highly abundant exosomal mRNAs that are listed in Table 3.1, such as Eif4ebp2,
Fth1, Tcf20, and Mlec, were associated with cluster 1. High background levels of
expression in CTLL2 cells of these transcripts coupled with the technical noise associated
with RNA-seq analysis rendered the difference between untreated and exosome-treated
CTLLs as not significant. Mela was an exception as it was not observed in any of the RNAseq samples.

Figure 3.6. Exosomes deliver an mRNA payload. An increase in transcript
abundance observed by RNAseq following exosome treatment correlates with
mRNA payload contained within B16F0 exosomes as assayed by cDNA microarray.
(A) For transcripts detected above background using cDNA microarray, an increase
in transcript abundance in exosome-treated cells over untreated cells after 0.5
hours (mean ± SD, n = 3) was plotted against the average fluorescence intensity for
the corresponding transcript probeset assayed by cDNA microarray (mean ± SD, n
= 4). A linear relationship was quantified by a correlation coefficient of 0.902. While
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highlighted in panel A, RNAseq results for four of the most abundance transcripts
across experimental conditions (exosome treated: circles and black solid lines,
untreated: squares and red dashed lines) are shown separately for Wsb2 (B),
Fam168b (C), Cmtm4 (D) and Ptpn14 (E).

Of note, cluster 1 is associated with transcripts that increase with exosome-treated
samples almost immediately. In contrast, clusters 2 and 3 develop over the course of 8
hours. We also noted that there were no transcripts that decrease in direct response to
exosome treatment. This lack of a response has implications for the miRNA exosomal
payload. There are three main functions associated with miRNA (Guo 2010). First,
miRNAs may bind to the 3' UTR complementary sequence of their target mRNA, thus
inducing gene silencing and prohibiting the translation of proteins from that segment.
Second, miRNAs may promote translational repression by cleaving and degrading mRNA
sequences. Third, miRNAs have been shown to deadenylate and degrade mRNAs upon
attachment. While all three functions of miRNA reduce protein abundance by interfering
with translation, only the second two functions alter mRNA abundance. Given that there
were no transcripts that were significantly decreased at the 0.5 and 2 hour time points, we
concluded that transcript downregulation through miRNA targeting the 3' UTR for
degradation is not a primary effect of exosome treatment. We note however that a
decrease in mRNA target abundance by miRNA becomes more apparent when the
miRNA is over-expressed, while exosomal delivery is closer to physiology.
Long non-coding RNA (lncRNA) can also regulate gene expression in cells
(Ponting2009, Mercer2013). As the Affymetrix microarray platform does not assay
lncRNAs, we used the RNA-seq data to identify lncRNA that were upregulated in CTLL2
cells upon stimulation with B16F0 exosomes. Given the concordance between mRNAs
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assayed in exosomes and their corresponding rapid increase in CTLL2 cells, we assumed
that the rapid increase in lncRNA observed in exosome-treated CTLL2 cells originated
from the B16 exosomes. There were two lncRNAs that were significantly increased in
exosome-treated

CTLL2

cells:

Gm26809

and

Gm26982.

Gm26809

(ENSMUSG00000097815) was upregulated at all exosome treated time points (0.5hr
untreated: 53 ± 11 counts, exosome-treated: 94 ± 14 counts, and p-value < 0.025). This
is a lncRNA that targets LSM8, which was observed to be decreased at the 8 hour time
point: (untreated: 988 ± 137 counts, exosome-treated: 719 ± 49, and p-value < 0.006).
Gm26982 is an antisense lncRNA (ENSMUSG00000097994) that was significantly
increased in exosome-treated samples at 0.5 hours (untreated: 57 ± 4 counts, exosometreated: 93 ± 19 counts, and p-value < 0.05). Gm26982 overlaps with the protein-coding
locus of ghrelin (Ghrl) on the opposite strand, although there was no significant difference
in ghrelin transcript abundance associated with exosome treatment at any time point.

3.2.3 Exosome-elicited transcriptomic signature in cytotoxic T cells becomes
apparent after 8 hours
As the changes in gene expression associated with cluster 1 appears to be a
direct result of exosome treatment, DE genes associated with clusters 2 and 3
characterize the secondary transcriptomic response to delivery of the exosomal payload,
as both take hours to develop. Comparisons of overall gene expression of clusters 2 and
3 as a function of time between exosome-treated and untreated samples are illustrated by
Fig. 3.7A-B, respectively. For genes associated with cluster 2, there was a significant
increase in transcript abundance in untreated cells at the 8 hr time point while transcripts
exosome-treated cells seemed to peak earlier at 4 hours and were not increased at 8
hours. The opposite effect was observed for cluster 3, whereby genes in untreated cells
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within cluster 3 undergo a reduction in transcript abundance at the 8 hour time point while
these same genes in exosome-treated cells tended to decrease at the 2 and 4 hour time
points and be upregulated at the 8 hour time point relative to untreated cells. Using the
genes associated with either cluster 2 or 3, we performed gene enrichment analysis to
identify cellular functions and pathways affected by the exosomal payload. As listed in
Table 3.2, DE genes associated with clusters 2 and 3 correspond to pathways essential
to cellular function and phenotypic maintenance.

Figure 3.7. Transcripts of genes associated with functional annotation of clusters 2
and 3 displayed different dynamic profiles. Average transcript abundance for
exosome-treated (solid black lines) and untreated (dotted red lines) for DE genes
associated with the functional annotation of cluster 2 (panel A) and cluster 3 (panel
B) are shown as a function of time. Transcript counts were normalized to the 0 hour
time points. (C) Normalized counts for E2F transcription factor 2 (E2f2) across
experimental conditions (exosome treated: X and black solid lines, untreated:
circles and red dashed lines) and time.
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Table 3.2 Gene lists enriched in dynamic transcription clusters 2 and 3.

Specifically, cluster 2 is enriched with transcripts related to cellular energetics and
mitochondrial function. The response of these genes with time was non-linear with an
increase in transcript abundance in exosome-treated CTLL2 cells at 4 hours relative to the
0 hour time point and to untreated cells at the 4 hour time point (p-value <0.001). In
exosome-treated CTLL2 cells, the abundance of these transcripts returned to baseline by
the 8 hour time point. In contrast, untreated CTLL2 cells increased expression of these
genes over time suggesting that CTLL2 cells would increase their mitochondrial activity;
yet, the timing between changes in gene expression and functional changes is unclear.
Given the values at 8 hours, one might conclude that untreated cells would have increased
mitochondrial activity as evidenced by annotation terms associated with this enriched
pathway as many directly relate to ATP production. To validate this functional annotation
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results, we assessed mitochondrial respiration in CTLL2 cells pre-treated with B16F0
exosomes for 16 hours and in untreated CTLL2 cells using a Seahorse XFe96 Analyzer
(Fig. 3.8A-D). Following the sequential addition of four chemical inhibitors, the measured
oxygen consumption rate was analyzed to obtain the basal respiration, maximal
respiration, ATP-coupled respiration, spare capacity, proton leak, and non-mitochondrial
respiration for these two experimental groups. Compared to untreated CTLL2 cells, basal
respiration, maximal respiration, and ATP-coupled respiration were significantly increased
upon exosome treatment. Non-mitochondrial respiration was also slightly increased in
exosome-treated cells. In contrast, spare capacity and proton leak were not significantly
different between groups. Generally, these changes in basal and ATP-coupled respiration
persisted at 48 and 72 hours, although the increase in maximal respiration diminished with
time. Similar results were obtained when we increased the efficiency of exosomal payload
delivery using the EV-Entry system. These functional results suggest that the observed
increase in gene expression in exosome-treated CTLL2 cells at 4 hours translates to an
increase in mitochondrial respiration.
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Figure 3.8. Exosomes alter mitochondrial respiration and cytokines in CTTL2 cells.
Exosomes increased aspects of mitochondrial respiration and IFNg production in
CTLL2 cells. (A) Oxygen consumption rate (OCR) in CTLL2 cells treated with culture
media (red circles) or media containing B16F0 exosomes (black circles) was
measured after 16 hour culture while the indicated chemical inhibitors of the
respiratory chain were sequentially added. As described in the methods, metrics
associated with mitochondrial respiration were inferred from the trace of the OCR
after 16 hours (B), 48 hours (C) and 72 hours (D). Significance associated with the
difference in basal respiration, maximal respiration, ATP-coupled respiration, nonmitochondrial respiration, space capacity and proton leak in exosome treated
(black bars) compared to untreated cells (red bars) were assessed. (E) IFNg and
TNFa were assayed in CTLL2 conditioned media by cytometric bead array following
the indicated treatments. (F) RNA-seq results for IFNg mRNA are shown for
comparison. Results representative of two independent experiments that each
contained at least four biological replicates, where ***, **, and * correspond to pvalues calculated using an unpaired t-test of < 0.001, < 0.01, and < 0.05, respectively.
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Cluster 3 genes are related to the regulation of gene expression and DNA
remodeling, including histone modification, histone methylation, and chromatin
modification. Covalent modifications to both histones and DNA regulate transcription
patterns within cells through mechanisms that alter the state of the nucleosome and
influence the ability of proteins to access DNA. Such modifications can silence genes.
Alternatively, a decrease in expression of genes that regulate the nucleosome suggests
that the epigenetic state of DNA is less regulated with time in untreated cells and that
some of the genes may no longer be effectively silenced. In contrast, epigenetic
modification of gene expression seems to increase in exosome-treated cells upon
prolonged tissue culture. In addition, a significant gene signature associated with cluster
3 is the down-regulation of genes, including Ncor2 and Crebbp that are shared with the
Notch signaling pathway, upon the loss-of-function of the transcription factor E2f2. Instead
of the loss-of-function, transcripts for E2f2 were observed to be significantly increased
upon exosomal treatment (Fig. 3.7C), which suggests that the exosomal payload activated
the Notch pathway in CTLL2 cells.
In contrast to intrinsic benefits to malignant cells (Zavadil 2004, Sahlgren 2008,
Lu2013), the impact on oncogenesis of activating Notch signaling in cytotoxic T cells by
tumor cells is less clear. One body of literature suggests that activating Notch signaling in
cytotoxic T cells enhances anti-tumor cytotoxicity. For instance, activated cytotoxic T cells
lacking both Notch-1 and Notch-2 receptors have a reduced proliferation and impaired
production of IFNg, TNFa and granzyme B (Sierra 2014, Backer 2014). By activating Notch
through transgenic expression of the intracellular domain of Notch-1, antigen-specific
cytotoxic T cells resist the immunosuppressive effect of tumor-induced MDSC and achieve
higher reduction of 3LL-OVA tumor growth (Sierra 2014). Notch signaling is also essential
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for differentiating short-lived effector cytotoxic T cells but is dispensable for generating
memory precursor cells (Backer 2014, Mathieu 2015. This body of literature implies that
an increase in Notch signaling would increase production of IFNg and TNFa. Functionally,
we observed that exosome treatment increased IFNg production while TNFa was not
increased over stimulating with IL-2 alone (Fig. 3.8E-F). In addition, CTLL2 cells did not
produce IL-6, IL-10, IL-12p70, or MCP-1 under the conditions tested. Similar results were
also obtained when we increased the efficiency of exosomal payload delivery using the
EV-Entry system.
While most of these studies blocked Notch receptors or genetically modified their
expression in cytotoxic T cells, the specific immune response depends on whether Notch
signaling is triggered by either Delta-like or Jagged ligands. Interestingly, delivery of antiJagged1 antibody or Delta1-Fc fusion protein exacerbates experimental autoimmune
encephalomyelitis in mice, whereas anti-Delta1 antibody or Jagged1-Fc fusion protein
ameliorate disease progression (Elyaman 2007). These opposing results were attributed
to differential regulation of T helper cells. Jagged1-Fc increases IL-10 producing T helper
cells and reduces Th1 polarization, while Delta1-Fc has the opposite effect (Elyaman
2007). In the context of antigen presentation, ectopic expression of Delta1 or Delta4 in
APC promotes Th1 differentiation while Jagged1 expression polarizes towards Th2
(Amsen 2004, Sun 2008). In vivo, injecting a soluble Jagged1-encoding plasmid reduces
the disease severity in an experimental arthritis model through the inhibition of cytotoxic T
cell proliferation and effector functions (Kijima2009). Therefore, a potential increase of
Notch signal activation in cytotoxic T cells by tumor exosomes could lead to activation or
suppression of this population depending on subtleties of the transcriptional response, as
similarly elicited by the Jagged and Delta-like ligands. While an increase in IFNg
production and the absence of IL-10 are suggestive, finer resolution of the specific
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transcriptional response would be required to identify the specific impact on cytotoxic T
cells by Notch signaling activation.
In summary, B16F0 exosomes seem to modify the epigenetic landscape and
mitochondrial respiration within cytotoxic T cells. In vivo, metabolic changes in tumor
infiltrating lymphocytes reflect the collective effect of metabolic substrate deprivation,
oxygen deprivation, and changes induced by tumor-immune cell crosstalk via a variety of
mechanisms, including exosome transfer. As these factors are confounded in vivo, we
have parsed the contribution of tumor-derived exosomes on immune cell function from
metabolic changes elicited in cytotoxic T cells by the tumor microenvironment by delivering
tumor-derived exosomes to cytotoxic T lymphocyte in vitro. While additional experiments
may help clarify the longer-term effects of exosome transfer on anti-tumor immunity, these
results suggest that B16 tumors produce exosomes that can alter mitochondrial respiration
of tumor-infiltrating cytotoxic T lymphocytes independent of substrate and oxygen
deprivation. Parsing how these mechanisms help condition the tumor microenvironment
is the first step in developing therapeutic strategies that can enhance the functional
persistence and efficacy of tumor-infiltrating cytotoxic T lymphocytes to control and
eliminate malignancy.

3.3 MATERIALS AND METHODS
3.3.1 Reagents and cell line culture
Cytokines, drugs, kits, and pharmacological inhibitors were obtained from commercial
sources and used according to the suppliers' recommendations unless otherwise
indicated. The mouse melanoma cell line, B16F0, and a cytotoxic T lymphocyte cell line,
CTLL2, were acquired from American Type Culture Collection (ATCC, Manassas, VA).
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Base media for CTLL2 cells included RPMI 1640 (Cellgro/Corning, Tewksbury, MA)
supplemented with 10% heat-inactivated fetal bovine serum (FBS-HI, Hyclone, GE
Healthcare Life Sciences, Marlborough, MA), 2.5% Glucose, 0.15\% sodium bicarbonate,
10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 100
µg/ml

streptomycin

(Pen/Strep,

Gibco,

Gaithersburg,

MD),

and

0.4%

beta-

mercaptoethanol. Complete media for CTLL2 cells comprised base media supplemented
with 10% T-STIM without ConA (Corning). B16F0 complete media was DMEM
(Cellgro/Corning) with 10% FBS-HI, Pen/Strep, and 2 mM L-glutamine (Sigma-Aldrich, St.
Louis, MO). Extracellular vesicle (EV)-cleared media was prepared by removing EVs from
the FBS-HI via ultracentrifugation, as described in the next paragraph, prior to making
complete media.

3.3.2 Exosome isolation, electron microscopy (EM) imaging and Western blot
analysis
Fresh extracellular vesicles were isolated from serum-free media conditioned by
B16F0 cells for 24 hours and imaged with scanning electron microscopy (SEM) as
described previously (Klinke 2014, Wu 2015). Briefly, EVs were isolated from cellconditioned media by differential centrifugation as follows: 300xg for 10 minutes to remove
cells, 2,600xg for 10 minutes to remove residual cells and debris, 10,000xg for 60 minutes
to remove microvesicles, and 100,000xg for 2 hours to collect nano-scaled vesicles in
pellets. The resulting pellet was resuspended, washed once in DPBS, and re-pelleted at
100,000xg for 2 hours. Once isolated, nano-scaled vesicles were resuspended in DPBS
and kept on ice. EVs were then imaged using SEM. The abundance of proteins contained
in B16F0 EVs were compared against B16F0 whole cell lysate by Western blot analysis
using methods described previously (Wu 2016). Specifically, membranes were probed
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with rabbit anti-CD9, CD63, CD81, and Hsp70 antibodies (ExoAb Antibody Kit, System
Biosciences, Mountain View, CA), and mouse anti-b-actin (Clone 2A3) and b-tubulin
(Clone 2-28-33) antibodies (Santa Cruz Biotechnology, Dallas, TX). Proteins were
transferred to Bio Trace PVDF membrane (PALL Life Sciences, Pensacola, FL) and
detected using Pierce ECL Western Blotting Substrate (Life Technologies, Carlsbad, CA).

3.3.3. Cell stimulation with exosomes and RNA analysis
As described in (Wu2016), GFP was delivered to CTLL2 cells using fresh exosomes
isolated aseptically from B16F0-XPgfp cells, which were created with a lentivirus encoding
an N-terminal XPack-GFP fusion protein by following the manufacturer's instructions
(XPAK530PA-1, System Biosciences, Inc., Mountain View, CA). CTLL2 cells were cocultured with B16F0-XPgfp exosomes for the indicated times at a concentration of 1.0
mg/ml, and imaged using a Zeiss Axiovert 40 CFL fluorescent microscope using a
standard GFP filter set. The efficiency of exosome payload delivery was increased using
the EV-Entry System (System Biosciences, Inc., Mountain View, CA). After 24 hours,
treated CTLL2 cells were also washed three times with DPBS and imaged. Total RNA was
isolated from B16F0 exosomes and cells by TRIzol reagent extraction (Thermo Fisher
Scientific, Waltham, MA) or RNAeasy (Qiagen, Hilden, Germany), quantified using
Nanodrop, and analyzed by on-chip-electrophoresis using the Agilent Bioanalyzer 2100.
Message RNA isolated from B16F0 exosomes and cells were characterized using Mouse
GeneChip 1.0 ST Exon Arrays (Affymetrix, Santa Clara, CA), as described previously (Wu
2016). For miRNA analysis, four hundred nanograms of each miRNA sample was biotin
labeled using the Genisphere FlashTag HSR Kit (Genishphere, Hatfield, PA) according to
the manufacturer's instructions. The labeling of RNA was confirmed by Enzyme Linked
Oligosorbent Assay according Genisphere FlashTag HSR protocol. The 21.5 µl of biotin-
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labeled RNA with added hybridization controls was hybridized to the GeneChip miRNA
2.0 Arrays (Affymetrix) at 48°C and 60 rpm for 16 hours in GeneChip Hybridization Oven
640 (Affymetrix). GeneChip miRNA 2.0 Arrays were stained using FS 450\_0003 protocol
in Affymetrix GeneChip Fluidics Station 450. Briefly, biotin-labeled RNA was reacted using
washes with a solution containing a streptavidin-phycoerythrin complex, with an
intermediate treatment of biotin-labeled anti-streptadvidin antibody to amplify the signal.
Phycoerythrin labeling was detected within the Affymetrix GeneChip Scanner 3000 7G
plus using 532 nm light and detected by a photomultiplier tube. A miRNA QC Tool software
(Affymetrix) was used to check quality controls of hybridized chips. All chips that passed
quality controls were RMA normalized using miRNA QC Tool. Microarray data are
accessible through GEO SuperSeries accession number GSE102951.

For RNA-seq analyses, CTLL2 cells were grown in complete media for 24 hrs, and
then stimulated with fresh B16F0 exosomes resuspended in PBS, to a final exosome
concentration of 0.2 mg/ml. Following RNA isolation by TRIzol extraction and Nanodrop
quantification, RNA quality and integrity was determined using the Agilent Bioanalyzer
2100. Only RNA with RIN values >8.0 were used for RNA-Seq library preparation. RNASeq libraries were built with Illumina's TruSeq RNA Kit V2 (RS-122-2001, San Diego, CA)
as per manufacturer's protocol. All libraries were indexed in such a way as to ensure only
one index/lane on the HiSeq. Finished libraries were quality checked with a High
Sensitivity DNA chip on the Bioanalyzer to determine average size and quantified on a
Qubit with high sensitivity DNA reagents. The libraries were then sent to the Marshall
University Genomics Core Facility where they were pooled in equimolar ratios and run on
three lanes of an Illumina HiSeq1500 in a 2 x 50 base paired end design yielding a
minimum of 49.1 million reads per sample. Samples included three independent biological

- 114 -

replicates for each condition and four independent biological replicates for the 0 hr time
point. Demultiplexing of samples and conversion from Illumina's bcl format to standard
fastq format was performed using CASAVA 1.8.4 (Illumina). The average transcriptomic
alignment percentage was 86.0 ±1.0%. RNA-seq data are also accessible through GEO
SuperSeries accession number GSE 102951.

Quantitative reverse-transcription PCR (q-RT-PCR) was used to validate the
mRNA and miRNA microarray results. The results for mRNA analysis are described
previously (Wu 2016), where proprietary primer mixtures were purchased from Qiagen for
the

corresponding

genes:

Kpnb1

(QT00153419),

Rnf14

(QT00157241),

Rnd2

(QT00314216), Ptp4a3 (QT00138243), Eif2c2 (QT01757833), Hipk2 (QT00197890),
Eif4ebp2 (QT00144606), Dnmt3a (QT00106519), Wsb2 (QT01747739). For miRNA
validation, RNA samples were purified using an RNeasy mini kit (Qiagen) and reversely
transcribed with TaqMan MicroRNA Reverse Transcription kit (Invitrogen 4366596).
Quantitative PCR was carried out on an ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems) using Taqman Universal Master Mix II with UNG (Invitrogen
4440038). TaqMan Primer mixtures were purchased from Invitrogen for the indicated
miRNA targets: mmu-miR-720 (Assay ID: 001629), mmu-miR-34c* (Assay ID: 002584),
mmu-miR-34b-3p (Assay ID: 002618), mmu-miR-1949 (Assay ID: 121182\_mat), mmulet-7d* (Assay ID: 001178), mmu-miR-31 (Assay ID: 000185), mmu-miR-378a-3p (Assay
ID: 002243), mmu-miR-709 (Assay ID: 001644), mmu-miR-467F (Assay ID: 002886), and
mmu-miR-181a-5p (Assay ID: 000480).
Data was analyzed using the delta/delta CT method and the Sequence Detector Software
version 2.2 (Applied Biosystems).
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3.3.4. Mitochondrial respiration and other functional assay
Oxygen consumption rate (OCR) was measured at 37°C using a Seahorse XFe96
Analyzer (Agilent, Santa Clara, CA) according to the manufacturer's instructions. Briefly,
CTLL2 cells (100,000/ well) were seeded into Seahorse Bioscience XFe96 cell culture
plates previously coated with Cell-Tak (Corning, Inc., Corning, NY). Fresh B16F0
exosomes were added to a final concentration of 0.2 mg/mL. After overnight culture in the
37°C humidified incubator with 5% CO2, the media was changed to Mito-Stress Test
Assay Media, which is DMEM containing 2 mM GlutaMax, 1 mM sodium pyruvate, and 25
mM glucose (media is un-buffered, pH 7.4), and incubated at 37°C without CO2 1 hr prior
to the start of the extracellular flux assay. Oligomycin, carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone (FCCP), rotenone and antimycin A (all from Sigma,
St. Louis, MO) of 10x compound dilutions were prepared for the assay as chemical
inhibitors, and loaded into the assigned ports. A sensor cartridge was calibrated 24 hr prior
to the assay, and following calibration, the cell plate was placed in the Bioanalyzer and
the Mito-Stress Test assay protocol was completed on the samples. By adding the
chemical inhibitors sequentially, this protocol determines basal respiration, ATP
production, maximal respiration, spare respiratory capacity, proton leak, and nonmitochondrial respiration. Statistical analysis was done with unpaired t-test using
GraphPad Prism 5 (GraphPad Software, San Diego, CA).

Cytokines produced by CTLL2 cells were measured in culture supernatants using
a Cytometric Bead Array Mouse Inflammation kit and a BD LSRFortessa flow cytometer
(BD Biosciences, Sparks, MD), according to the manufacturer's instructions. Viable cell
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numbers were quantified using an ATPlite assay (PerkinElmer, Shelton, CT), performed
according to the manufacturer's instructions. For these assays, CTLL2 cells (20,000/well)
were cultured for 48h in 100 µL of base CTLL2 media supplemented with 10 U/mL of
recombinant murine IL-2 (eBioscience, ThermoFisher Scientific). Fresh B16F0-derived
exosomes were added to a final concentration of 0.2 mg/mL. Conditioned media was then
saved for cytometric bead analysis. For the ATPlite assay, the cells were treated with 50
µL/well of mammalian cell lysis solution, followed by 5 min. shaking. The substrate solution
was added (50 µL/well), the plate was shaken another 5 min., and incubated 10 min. at
room temperature protected from light. Finally, the luminescence was measured using a
modulus microplate multimode reader (Turner BioSystems). CTLL2 cells cultured in base
media supplemented with IL-2 but in the absence of B16F0 exosomes, as well as CTLL2
cells maintained in base media free of IL-2 and tumor exosomes, were included as
controls. Statistically significant differences were detected with one way ANOVA and
Tukey's multiple comparison test using GraphPad Prism 5 (GraphPad Software).

3.3.5 Computational transcriptome analysis and statistics
Using the WVU Spruce Knob High-Performance Computing (HPC) cluster, fastqformatted files were combined based on both lane designation and forward/reverse
orientation. Quality control analysis was performed using the FastQC program to
determine that trimming was not necessary prior to completing further downstream
processing of the files. The Mus musculus FASTA file and a corresponding gene set
annotation (GTF) file were downloaded (GRCm38.p2 from ensemble.org) to compile a
genome index using STAR Aligner software (v2.4.2). Genome annotation files were
comprehensive in that they included mappings for both exon and intron segments for the
full selected genome. RNA sequence reads were then aligned to the index with STAR
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Aligner tools, converted to .bam files, sorted, and indexed. To determine the number of
reads mapped to each genomic position or exon, the featureCounts program (v1.5.0)
within the Subread package was used.

The remaining portion of the analysis was performed using R software platform
(v3.3.2) along with Bioconductor packages. Using featureCounts files, the DESeq2
package (Love 2014) was used to determine the top differentially expressed genes by
comparing the exosome-treated versus untreated samples at each time point and
untreated samples at each time point relative to the 0 hour time point. A p-value adjusted
for multiple hypothesis testing of less than 0.1 at the 0.5, 2, and 4 hour time points and of
less than 0.04 at the 8 hour time point was considered significant. Transcript abundance
was reported as variance stabilized normalized counts, whereby summary statistics were
generated by averaging across all samples and standard deviation was used to represent
uncertainty. Functional annotation of the RNAseq data was performed on the temporal
clusters of differentially expressed genes associated with exosome-treated samples using
the Enrichr algorithm (Chen 2013, Kuleshov 2016). Additional microarray data containing
both mRNA and miRNA samples was analyzed using R software. For microarray
analyses, mRNA and miRNA abundance was estimated based on the average expression
of all core probesets for a target measured by Affymetrix microarray. The probability of a
mRNA/miRNA being detected above background (DABG) by random chance was
estimated using the negative control probe sets and a Welch's t-test, where the degrees
of freedom were calculated using the Welch-Satterthwaite equation. An adjusted p-value
of less than 0.05 was considered as statistically significant. Functional annotation of
exosomal miRNAs was determined using a multi-step approach in R. First, results from
the Affymetrix GeneChip miRNA 2.0 microarrays were filtered based on the expression of
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Mus musculus miRNAs in exosomal samples detected above background. Next, the
miRNAtap package (v1.10.0) was used to relate specific miRNA with targeted mRNA
transcripts based on aggregate predictions from at least 3 databases, which include
DIANA, Miranda, PicTar, TargetScan, and miRDB (Pajak 2016). Gene sets associated
with canonical pathways was obtained from the Molecular Signatures Database v6.0 at
the Broad Institute (Subramanian 2005). Finally, the miRNApath package (v1.36.0) was
used to identify enriched pathways associated with the miRNA expression data, where the
number of permutations was set to 1000 (Cogswell 2008).
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CHAPTER 4: REVIEW OF QUANTITATIVE SYSTEMS PHARMACOLOGY FOR THE
FUTURE DEVELOPMENT OF CANCER IMMUNOTHERAPIES

The return on investment within the pharmaceutical industry has exhibited an exponential decline
over the last several decades.

Contemporary analysis suggests that the rate-limiting step

associated with drug discovery and development process is our limited understanding of the
disease pathophysiology in humans that is targeted by a drug. Similar to other industries,
mechanistic modeling and simulation has been proposed as an enabling quantitative tool to help
address this problem. Moreover, immunotherapies are transforming the clinical treatment of
cancer and are becoming a major segment of the pharmaceutical research and development
pipeline. The clinical benefit of these immunotherapies seems to be limited to a subset of the
patient population. Identifying the specific defect in the complex network of interactions associated
with host immunity to a malignancy is a major challenge for expanding the clinical benefit.
Understanding the interaction between malignant and immune cells in inherently a systems
problem, where an engineering perspective may be helpful. The objective of this chapter is to
summarize this quantitative systems perspective, particularly with respect to developing
immunotherapies for the treatment of cancer.
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4.1. INTRODUCTION
Motivated by a desire to improve human health, the pharmaceutical industry leverages
biological discoveries to develop drugs that aim to restore health at significant financial
investment. Overall the costs associated with pharmaceutical research and development,
as represented by the US share of the market, has been increasing exponentially. The
current estimate to bring a new medical entity to market requires upwards of approximately
a $1–2.5 billion investment in research and development (PhRMA 2013, Mullin 2014). To
recoup these financial investments, pharmaceutical companies are provided with
protection from competition for a limited time by patenting their inventions. However, the
estimated return on investment by the pharmaceutical industry has been experiencing an
exponential decline in the last several decades. This trend, sometimes referred to as the
innovation gap, presents a challenge for economic sustainability of the current model for
innovation within the pharmaceutical industry.
The cost of pharmaceutical development escalates as drugs progress further from bench
to market. In particular, Phase II clinical trials have become a key pinch point in the
research and development pipeline, as it combines both significant risk and cost. This
phase is the first time the efficacy of the drug is tested in real patients within the target
disease and therefore has the highest probability of failure. It is also one of the phases
with the highest out-of-pocket cost for the developer and other stakeholders (Chen and
Beckman 2014). Clinical trials are predicated largely on positive pre-clinical studies using
animal models of disease. Unfortunately, animal modeling, which presents lower financial
and human health hazards, may not always recreate the specific molecular and cellular
networks associated with the pathophysiology and adverse reactions in human subjects
(Wartha 2014). Therefore, to lessen the costs of development and risk to humans in
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clinical trials, it is important to use appropriate models of the disease to maximize efficacy,
safety, and benefit to patients.
In the last 50 years, computer-aided modeling and simulation has transformed a variety
of industries, including financial portfolio management and the aerospace industry.
Modeling and simulation in the financial sector has enabled real-time evaluation of
economic performance measures using a mathematical model of the particular business
sector to predict future performance and to optimize financial return (Dailami 1999). In the
aerospace industry, modeling and simulation is used to design new airframes, which
eliminates the need for multiple physical prototypes constructed at intermediate points
during design and reduces the time from concept to production (Mavris 1999). In both
cases, mathematical modeling and simulation provide a quantitative framework to capture
our conceptual understanding of the modeled process and interpret heterogeneous data
acquired from the process. These two examples also represent extremes of our
conceptual understanding. Financial markets are complex systems that are influenced by
a variety of observed and unobserved factors. Assuming that the underlying structure of
the market is not changing, future behavior can be predicted using empirical mathematical
models that are constructed using historical data. At the opposite end of the spectrum,
computer-aided design of airframes captures physical principles such as the conservation
of mass, which implies two physical objects cannot occupy the same space, and the
governing physics associated with the performance objectives of the airframe. Similar to
these industries, mathematical modeling and simulation has been proposed as approach
to improve our understanding of the biological mechanisms targeted by a particular
therapy (Lauffenburger and Giacomini 2013). This could help predict the outcomes of
human clinical trials and, thereby, help bridge the innovation gap between cell and animal
models and human pathophysiology, while also providing a cost savings in development,
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as computationally “expensive” modeling is inherently more cost effective than additional
physical and biological models of disease (Ananthakrishnan and Gona 2010). In a 2011
National Institutes of Health White Paper, recommendations for quantitative systems
pharmacology using quantitative experimental studies and model-based computational
analyses that also incorporate clinical “omics data” were given in hopes of addressing
clinical Phase II study failures in drug development and physiological, chemical, and
biological disconnects in preclinical research (Sorger 2011).
Given the oncology slice of pharmaceutical research and development and the recent shift
towards immunotherapies for cancer, the objective of this review is to summarize how
modeling and simulation has aided in the understanding of biological changes associated
with oncogenesis as it relates to immunity. In subsequent paragraphs, we provide a brief
overview of the cancer and immune systems, tumor somatic and clonal evolution
properties, and how cancer cell heterogeneity complicates therapeutic aims. We will also
discuss recent immunotherapeutic advancements and the computational models used to
describe the interactions between cancer and the immune system.

4.2. EMERGING VIEW OF CANCER AS A SYSTEM
Oncogenesis is attributed to the accumulation of genetic mutations that lead to
uncontrolled cell growth and proliferation. These mutations alter function of the modified
gene through overexpression of the corresponding protein or rearrangement of a gene to
create an entirely new protein that has dysregulated activity (Radulescu 2013). Mutations
in specific genes that can, in isolation, transform a normal cell into a malignant cell are
called oncogenes. Cancer drug development over the past several decades has been
focused on targeting these oncogene mutations by inhibiting the function of corresponding
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proteins using small molecule drugs (Arnedos 2014). Researchers have scrutinized the
altered signaling pathways in malignant cells in hopes of finding the key protein conserved
in oncogenesis and metastasis but that plays minimal role in normal cells (Li 2014).
However, these drugs are rarely as efficacious in the clinic, where de novo and emergent
drug resistance is common (Ramos 2014).
The small molecule inhibitor segment of the pharmaceutical industry is also associated
with a view of cancer as a disease driven by malignant alterations that are intrinsic to or
driven by the cancer cell (Weinstein and Joe 2006, Ellis 2009). This view can be
represented by the six hallmarks of cancer discussed by Hanahan and Weinberg 2000
(Hanahan and Weinberg 2000). The six hallmarks summarize how genetic alterations
change how a malignant cell senses and responds to extracellular signals in ways
detrimental to the host. Assuming cancer is driven by the autonomous actions of malignant
cells, the in vitro study of a cell line can be an appropriate model for identifying new
therapeutic leads. This idea underpins using a collection of cell lines as a way to screen
drugs that inhibit cell proliferation of exhibit cytotoxic activity in a high-throughput manner,
such as the NCI-60 (Shoemaker 2006, Monks 1991, Paull 1989, Wong 2012).
Previously to recent breakthroughs in immunotherapy, small molecule inhibitors were
standard of care for many non-resectable metastatic diseases. B-Raf, a Raf kinase
member of the MAP Kinase/ERK signaling pathway and involved in cell growth and
proliferation, is a commonly mutated gene in many human cancers, such as metastatic
melanoma. Vemurafenib and Dabrafenib are two FDA-approved B-Raf inhibitors used in
the clinic that targets cancer with the B-RAF V600E (valine at amino acid position 600 to
glutamic acid) mutation. However, cancer cells without the V600E B-Raf mutation may
proliferate more in response to the vemurafenib drug (Chapman 2011). Additionally, most
metastatic melanoma patients become chemoresistant to both of these B-Raf inhibitors
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within 6 to 7 months of treatment. Therefore, combination therapies, such as vemurafenib
with MEK-inhibitors like FDA-approved trametinib, are preferred to overcome the
resistance mechanism in advanced melanoma, and may extend progression-free survival
in patients by an average of about 3 months (Flaherty 2012). However, resistance will
eventually reoccur and the patient will fatally relapse.
More recently, cancer research has expanded to include factors external to the malignant
cell that contribute to oncogenesis. In 2011, Hanahan and Weinberg updated the
hallmarks to include four new “emerging hallmarks and enabling characteristics”, which
focus on changes associated with the malignancy that alter interactions among cells of
the host (Hanahan and Weinberg 2011). The immune system was identified as having an
influential role on tumor progression, and changes in metabolism and inflammation in the
tumor microenvironment and throughout the body are known to have an effect on clinical
outcomes, as well. This shift in perspective represents a malignancy as part of an
integrated but dysfunctional system, rather than as an isolated mass of malignant clones.
By incorporating the emerging hallmarks into the collective understanding of
carcinogenesis, the ability of a malignant cell to manipulate its local environment and the
immune system that it interacts with are being recognized as integral to tumor
development and support the description of cancer as an evolutionary process (Figure
4.1). The ability of a malignant cell to maintain the tumor microenvironment hinges on
dysfunctional intercellular communication (Polyak 2009, Tlsty 2006).
A tumor is comprised of a variety of cell types, including a heterogeneous collection of
malignant clones, various stromal cells that provide nutrients and facilitate remodeling of
the extracellular matrix, and immune cells. Heterogeneity among malignant clones can
exist within various morphologies or cellular phenotypes, producing cells originating from
a similar origin, but may yet exhibit various structural, gene expression, signaling network,
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proliferative, metabolic, and metastatic differences (Figure 4.1). The existence of
heterogeneity is a key element of evolutionary process. Somatic evolution is thought to
change the dynamics of tissues (Gatenby and Vincent 2003, Michor 2004), while
evolutionary processes also maintains their own dynamics (Nowak 2003), both of which
can influence development of heterogeneity within a particular cellular population.
Resolving the issues surrounding multiple dynamics of biological systems and the
influence of the immune and other cellular systems on tumors is technically difficult to
replicate, particularly in in vitro models of cancer. The dynamics of cell communication can
also influence the hallmarks of cancer of a potential malignancy and emerging hallmarks
can alter the fitness, adaptive, or phenotypic landscapes (Klinke 2012, Mahadevan 2011,
Schreiber 2011). Timing of response to signaling, especially that of the immune system,
can mean the difference between malignancy proliferation and tumor eradication (Rech
and Vonderheide 2013).
As part of the evolutionary process, recognizing the heterogeneity of the environment is
crucial to understanding how alterations in cell signaling and immune response may
promote tumors. Cancer cell heterogeneity within some tumors is linked to epigenetic
differences in tumor cell genomes, perhaps from variances in cancer stem cells, while
other examples of divergence from a single phenotype can be accounted for through
clonal evolution, or even a combination of the two models of tumor propagation (LaBarge
2010, Shackleton 2009). Therefore, we see that clonal evolution and heterogeneity are
directly proportional to one another and will determine impact of immunological eradication
or pharmaceutical treatment of the tumor. The remainder of this section will discuss
models of somatic and clonal evolution and influence of heterogeneity of the tumor
microenvironment on metastatic progression from a systemic perspective of cancer.
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Figure 4.1. Progressive view of tumor microenvironment. An illustration of the
conceptual progression of the tumor microenvironment from a reductionist view to
cancer as a dynamic system. (A) A highly reductionist view. Tumors viewed as a
homogenous population malignant clones; (B) Cancer cells integrated into the
circulatory system, as represented by including blood vessels and fibroblasts, as
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seen in Hanahan and Weinberg 2000; (C) The tumor microenvironment becomes
more complex. In addition to blood vessels and fibroblasts, immune cell types of
various kinds are introduced into the system, as seen in Hanahan and Weinberg
2011; (D) The emerging view of a malignancy as a heterogeneous and dynamic
system. Not only are blood vessels, fibroblasts, and immune cells in the tumor
microenvironment, but there are distinct clonal populations of cancer cells
intermingled with a variety of different immune cells and other cell types.

4.2.1. Somatic Evolution
Somatic evolution, as distinct from classical Darwinian evolution, is a driving force
for carcinogenesis (Meacham and Morrison 2013). The majority of somatic mutations
within the genome are neutral, but accumulations of even non-deleterious mutations can
alter the fitness landscape of an organism via genetic drift (Merlo 2006, Knudson 2001).
Changes in the fitness landscape include alterations in cellular communication (Gatenby
2008), such as upregulation or downregulation of receptors, intermediate players, or
downstream products, alterations in pathway activity, or mutations in pathway protein
partners. This can promote selection of advantageous clones (Casas-Selves and
Degregori 2011) More importantly, these malignant clones can change the fitness
landscape in such a way that the local microenvironments become a favorable niche for
malignant cells. A particular case of somatic evolution is clonal evolution, which considers
how the environment influences the selection of pre-existing clones within a
heterogeneous population and neglects the influence of mutagens to further diversify the
clonal population. Somatic and clonal evolution may provide many benefits to a cell.
Changes in the environment of the cell may force it down a particular path, providing a
fitness advantage for growth and proliferation. While most of these particular mutations
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may provide benefit for survival of the host, these alterations can promote further genomic
instability, leading to tumorigenesis.
Reductionist theories and experimentation usually examines one input and one
output of a particular system, and therefore may be inadequate in describing cell
processes with appropriate models, especially in relation to somatic and clonal evolution
within a population. A cell is ever-sensing of its microenvironment, ready to respond to
relevant extracellular signals present in its vicinity, whether the cues are coming from other
cell types, other tissues, or from itself. These cues can also have a profound impact on
the evolution of a cellular population, depending on duration, strength, and ability of the
cell machinery to respond to the signal. This communication may come in the form of a
soluble ligand or direct cell contact and provide positive or negative feedback to the cell.
As a heterogeneous environment, a variety of signals are occurring and being processed
by the target cell at any time and are difficult to observe with traditional models. Various
factors, driven by cellular communication, can affect the fitness of a particular population
of tumor cells, such as availability of nutritional or metabolic resources, presence and
strength of immune system influences, and ability of the cell to interact with the
extracellular matrix. To combat this hurdle, development of a hybrid-discrete continuum
(HDC) model to examine tumor morphology and metastatic potential was developed by
Anderson et al. (Anderson 2006), which leverages the impact of multiple factors of the
tumor microenvironment on somatic or clonal evolution. This mathematical model allows
for “random” influence of particular set of variables, while retaining deterministic properties
of known inputs with known outputs.
Related to factors surrounding use of the HDC computational model is the “clonal
dominance theory” developed by Kerbel and colleagues. While clonal dominance was
easily observed in vivo in mammary tumors, replication under ideal growth conditions was
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difficult. The group examined the growth of two subpopulations, non-metastatic SP1 and
metastatic variant C1, of cells under both ideal and non-optimal growth conditions. Under
optimal conditions, both subpopulations of cells grew at the same rate, while under the
“stressed” conditions, emergence of the “dominant” metastatic subpopulation C1 became
evident. In addition, transforming growth factor-beta (TGFβ) and extracellular matrixdriven cell-to-cell communication between the two subpopulations was indicated as being
required for assistance of the dominant metastatic subpopulation to maximum capacity
(Rak and Kerbel 1993). This study highlighted the importance of culture conditions and
physiological dimensions, such as serum concentration and spheroid growth, for in vitro
work to best replicate in vivo tumors, given the importance of cell-to-cell communication
in tumor development and maintenance. However, researchers often overlook the effect
of these conditions on clonal evolution, and therefore, how these conditions may affect
whether a certain model is appropriate for judging efficacy of a treatment in in vitro or in
vivo experiments.
Other features that impact clonal dominance in the evolution of cancer include
consideration of compartment size. All tissues can be viewed as “compartments”. Clonal
expansion readily occurs within these compartments and can be restricted by neighboring
clones (Mintz 1967). As shown by Michor et al. in a mathematical modeling study, clonal
expansion within a small compartment is driven by genetic drift and is quickly dominated
by a certain genetically unstable subpopulation. However, the expansion is readily limited
by boundaries of the compartment and is therefore likely to be contained. Conversely,
large compartments will contain a variety of subpopulations, some tumorigenic; however,
the effect of clonal expansion is diluted unless both alleles of a particular gene are
affected, or selective advantage favors the tumorigenic subpopulation (Michor 2003).
Once a tumorigenic subpopulation has taken over the compartment, success of the
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neoplasm and resulting metastasis is a more probable scenario. This highlights the
importance of cell-communication through cell-to-cell contact and local regulation of
homeostasis in limiting genomic instability. Experimental cell models may reflect these
effects, and therefore cellular confluency in vitro, or tumor transplant location in vivo may
affect treatment outcomes.
Driver mutations and passenger mutations are another area of investigation in
regards to computational models of the evolution of cancer. Driver mutations result in
functional or morphological differences of cells, while passenger mutations are a neutral
consequence of the evolutionary process (Gatenby 2014). In a meta-analysis study of lung
and ovarian cancer, Youn and Simon found that metastasis as a result of cancer evolution
was related to the age of the tumor and number of cell generations. The difference in
metastatic potential as a function of generation or age of the tumor was related to the
ability of the parental lineage to self-renew. For example, more generations were required
for ovarian cancer to metastasize versus the lung cancer cell, which self-renews more
gradually. The study was conducted by using passenger mutations, which do not confer
a selective growth advantage in clonal expansion of the tumor, to estimate when the driver
mutation, developed in the early stages of tumorigenesis and linked to causation of the
tumor, had occurred and therefore, the approximate generational age of the tumor (Young
and Simon 2013). This study highlights the tumor progression differences in cell line or
cancer types are largely attributed to clonal differences and how this may have an effect
on treatment outcomes, not only in cell and animal model experiments, but also in the
clinic.
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4.2.2. Heterogeneity of the Tumor Microenvironment
We have examined the effects of clonal expansion in tumorigenesis and how
compartment size and tissue dynamics may affect this process. Clonal expansion implies
a somewhat homogenous subpopulation of cells dominates a certain microenvironment,
compartment, or tissue. However, the heterogeneity of tumor microenvironments and
tissues is well described (Peterson 2014). Not only does the tumor stroma contain different
cell types, such as immune cells, and structural support cells, but tumor cells themselves
are part of a heterogeneous population. Different subpopulations of various clones exist,
each expressing a variety of biomarkers and each clone with their own signaling dynamics,
within the total tumor cell population.
Analysis of National Cancer Institute (NCI) and National Human Genome
Research Institute (NHGRI) TCGA (the Cancer Genome Atlas) Project has revealed that
sequencing of human tumors has provided a wealth of genomic information. The goal of
this project was to determine common genetic alterations in various cancer types and
subtypes, and use this information to improve clinical outcomes and tailor therapies to
individuals. However, the impact of this data on improving clinical outcomes or identifying
successful drug targets within corresponding patient groups remains limited. While the
TCGA project was conceptually born out of the oncogene perspective, recognizing that
tumors contain a variety of heterogeneous tumor clonal populations and prevalence within
these clonal subsets of varying abundance could have a profound impact on the
information gathered and possibly skew data interpretation (Li 2014). Molecular-targeted
therapies focusing on one set of genetic alterations would have little effect on a
subpopulation expressing an entirely different set of alterations, as seen within the
heterogeneous tumor. This may be one reason combination therapies have been so
effective in treating certain types of cancer, as seen with the synergistic effect of p53
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vaccines and chemotherapy in an evolutionary double bind study conducted by Anderson
and colleagues (Basanta 2012).
As discussed previously, clonal evolution plays a critical role in the development
of a tumor, but tumor heterogeneity may be a critical aspect for tumor persistence.
Different tumor clonal populations may allow for evasion of the immune system. If tumor
antigens produced vary from cell to cell within the tumor, a targeted immune system
response will become diluted, allowing immunoescape of the tumor. This type of clonal
selection provides for a phenomenon described as immunoselective pressure. By allowing
for targeted killing of a specific tumor cell population expressing a given antigen, other
tumor cell populations may be able to fill the tumor niche, especially cell populations that
do not express an immunogenic antigen. Tumor cells sensitive to the inflammatory
response, generalized apoptosis signals, or other factors in the microenvironment, may
also be eliminated, while more resistant cells are allowed to proliferate. Additionally,
cytokines may provide selective pressure to develop mutations that result in clones that
are able to overcome these immune signals targeting the cells for destruction (Mumm
2008). This phenomenon is called immunoediting. A deadly combination of elimination of
immune-sensitive tumor cells, equilibrium of tumor cells that have survived elimination,
and escape of resistant clones limits tumor eradication by the immune system (Dunn
2004).
Clonal heterogeneity can also provide survival advantages depending on the
location of the clonal subset within the tumor microenvironment. Mutations that promote
angiogenesis, for example, would provide a survival advantage in a tumor region not within
immediate contact of the vasculature and perfusion of blood and nutrient resources.
Alternatively, mutations that upregulate multidrug resistance transporters would provide a
survival advantage in areas of the tumor that is most susceptible to contact with

- 139 -

chemotherapeutic agents, such as in the periphery of the tumor that is most accessible to
drug delivery. To explore this relationship between tumor heterogeneity and persistence,
a computational study by Michor and colleagues examined the effect of immune system
response and chemotherapeutic interventions in tumor escape (Iwami 2012). They
developed a mathematical model to describe original tumor cell and variant tumor cell
fitness and number, mutation rate of the cancer cells, competition between variants, tumor
cell elimination rate, interactions between tumor cells and cytotoxic T lymphocytes (CTLs),
and the proliferation and decay of CTLs. They found that the more variants that exist within
a tumor, the more likely the tumor will catastrophically or partially escape from immune
system or chemotherapy attack. However, a certain level of homeostasis in variation must
be maintained to support a functional genome for survival of the tumor.
In summary, a tumor is not only heterogeneous in its various clonal populations
and expression of various tumor antigens, but is also heterogeneous in terms of
weaknesses. By directing therapy at several weaknesses at once, instead of one at a time,
or by targeting the interplay between tumor and other systems it interacts with, this lessens
the probability of a certain clonal population gaining proliferative momentum in the tumor
niche. Tumor heterogeneity is extremely important for the success of a tumor cell in the
microenvironment and relies on the dynamics between the immune system, rates of
genetic alterations, and sensitivity of variants to chemotherapeutic or immune system
attack.

4.3 THE RE-EMERGENCE OF CANCER IMMUNOTHERAPY
The immune system has long been suspected as influential on cancer
development. In the early 1890s, Dr. William Coley noticed a reduction in tumor size of
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patients with bacterial infections. He began injecting live bacteria into the tumors, and later
developed a safer concoction, termed “Coley’s toxins”, with mixed results (Zacharski
2005). Over time, the field shifted away from cancer immunology research, as cytokines
and immune cell types became well defined, yet cancer treatment with interleukins and
other cytokines yielded variable results. Interleukin-2 showed efficacy in treating
metastatic melanoma. However, its adverse side effects, inefficacy in large tumors, and
high rates of toxicity such as allergic reactions and seizures discouraged widespread use
in patients (Heywood 1995, Karp 1996, Alexandrescu 2005, Moreno-Ramirez 2014).
Interleukin-12 was also investigated as a cancer drug for its robust anti-angiogenic and
immune cell-promoting activity. Although it had shown promise in preclinical trials, a
patient death in a study designed to test safety diminished enthusiasm to pursue systemic
delivery of IL-12 as a potential therapeutic (Zagozdzon 1999, Zagozdzon and Golab
2001).
Most of the failures of immune cell-promoting cytokines to eradicate tumors in
patients could be attributed to inappropriate animal models and the lack of target
specificity of these immunotherapeutic agents, as seen with the inability of cytokines to
possess the sensitivity and specificity to function as appropriate biomarkers (Schetter
2010). In an effort to gain specificity, antibodies, such as Rituximab, were developed and
approved for the treatment of cancer (Grillo-Lopez 2000). This development of antibodies
to target cancer has continued to this day, with the break-through of ipilimumab in
metastatic melanoma (Wolchok 2013). Through this process of repeated success and
failures, the view of cancer immunology has changed, and once considered a flame
extinguished, has reignited from the embers.
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4.3.1 The Cancer Immunology System and Systems Therapeutics
The view of cancer and the immune system as an integrated system is an
important perspective to develop additional targets for cancer immunotherapy. Being
cognizant of the interplay of systems is the first step to developing an appropriate model
to test hypotheses. As described by Chen and colleagues, the “cancer-immunity cycle”
involves an intricate process of cancer cell antigen recognition by the immune system,
immune cell trafficking and tumor infiltration, and a localized immune response to
eradicate the tumor (Chen and Mellman 2013). At each step of the process, a variety of
cytokines may be expressed to promote or inhibit the immune response. Checkpoints in
this process exist to support a balance of effective activity to maintain tissue homeostasis
and discourage fluctuations that could lead to the extremes of immunosenescence or
autoimmunity. The following paragraphs, we will discuss oncolytic viruses, adoptive cell
transfer, chimeric antigen receptors, and immune checkpoint modulators, in context of
their role in the cancer-immunity cycle. Each is able to alter feedback mechanisms to
promote the cancer-immunity cycle via various methods. The advantages and
disadvantages of each of these therapies will also be discussed.

4.3.1.1. Oncolytic Viruses
Oncolytic viruses are used to target and kill cancer cells. There are two methods
used to target the oncolytic viruses to kill only cancer cells, and they can be used in
combination to promote efficacy of tumor-targeted killing. Transductional targeting of
oncolytic viruses entails modifying the viral coat proteins of the virus to target malignant
cells preferentially by inhibiting the entry of the virus into non-cancerous cells. Nontransductional targeting genetically alters the virus so that it may only replicate in the
targeted cancer cell, whereby tumor-specific transcriptional promoters are used (Verheije
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and Rottier 2012). However, the host immune response to oncolytic viruses may vary
between individuals, and mechanisms of resistance to and effective delivery of oncolytic
viruses are poorly understood (Wong 2010). The variation among patients in immune
response to oncolytic viruses provides a significant clinical barrier to their use and efficacy.
However, oncolytic viruses may be used as an experimental tool to provide insight to
mechanisms of cancer evolution and immune system response in virally-mediated
cancers.

4.3.1.2. Adoptive Cell Transfer and Chimeric Antigen Receptors
A number of approaches have been proposed to jumpstart the cancer-immunity
cycle and maintain its efficacy. Adoptive Cell Transfer (ACT) expands T cell immunity to
a particular cancer antigen in the patient through isolation of T lymphocytes, population
expansion, and reinfusion. Cells can be genetically modified to recognize certain antigens,
to infiltrate tumors more readily, or to respond more robustly to cytokine cues (Chacon
2014). One example of genetic modifications that can be integrated into T lymphocytes in
ACT involves chimeric antigen receptors (CARs). These receptors are engineered to
recognize a specific antigen, which allows this treatment method to become tailored to an
individual type of cancer and the antigens it expresses (Kalos and June 2013). Use of
CARs in conjunction with ACT also overcomes a potential barrier with ACT and other
immune modulation therapies, which assumes that a patient’s T lymphocytes or that of a
donor will recognize the patient’s cancer cells and target them for killing. As shown by
Chacon et al. (Chacon 2014), using tumor-infiltrating CD8+ lymphocytes in ACT can also
have an impact on the rest of the tumor microenvironment, expanding a dynamically
regulated and more competent T cell population for killing of the tumor.
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ACT and CARs can be modeled mathematically in two ways: (1) through
mathematical modeling of the system effects and response of directed ACT and CAR
activity; and (2) by modeling molecular level CAR interactions. When designing CARs, it
is important to remember the effect of this type of therapy on the host’s system. The
plasmids used to express classical CARs use a signaling fragment, an extracellular
spacer, a co-stimulating domain, and an antibody to direct a specific response against the
tumor. However, using single-chain fragment variable (scFv) antibodies can cause
activation of the immune system in an undesirable manner. Single variable heavy chain
domains (VHH) have been shown to avoid immunogenicity. However, changing any
component of the CAR can lead to poor interaction of the receptor with its target. To
improve CAR targeting, molecular modeling can be used to predict interactions between
targets and the CAR with various components, such as a VHH directed against a particular
target (Pirooznia 2011). At the system level, a recent study by James and colleagues
modeled the target lysis achieved by alterations in chimeric T cell receptor (cTCR)
expression density, target antigen density, and activation of the cTCR. They found that
approximately 20,000 cTCRs per cell was an ideal density of expression of the surface of
the T cell. Anything above this did not increase target lysis or increase sensitivity to the
target antigen, and anything below this expression impaired target lysis activity, perhaps
by causing antigen-induced T cell death (James 2010).

4.3.1.3. Immune Checkpoint Modulators
Based on remarkable clinical success, the current immunotherapies that hold the
most promise are immune checkpoint modulators. Immune checkpoints are considered
natural negative feedback mechanisms that limit an adaptive immune response to
minimize the risk of autoimmunity. Investigation of immune checkpoint modulators has
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been on the rise in academia, biotechnology group, and pharmaceutical company
research (Pardoll 2012). It is also known that in late stage cancers, the immune system
appears to be turned “off”. Part of this “immune switching” phenomenon can be credited
to the tumor actively evading the immune response through its clonal evolution of certain
cellular subpopulations (Pawelec 2010). As an example, metastatic melanoma is arguably
one of the hardest cancers to treat and has very few treatment options in the clinic. As an
immunogenic cancer, it is known the immune system plays a role in progression of the
disease (Bombelli 2014). Therefore, the immune system was targeted as a potential
solution to molecular inhibitor resistance in metastatic melanoma and other cancers. The
particular proteins currently being examined for targeting include CTLA-4, cytotoxic Tlymphocyte antigen-4, and PD-1, programed death receptor-1, two regulatory molecules
on the surface of T cells (Ott 2013).
A neutralizing antibody against CTLA-4, called ipilimumab, improved overall and
progression-free survival in metastatic melanoma (Hodi 2010) and was the first FDAapproved therapy to target cancer through an immune checkpoint blockade. While clinical
benefit was observed in only a subset of patients, ipilimumab demonstrates an important
proof-of-principle especially in metastatic melanoma. Anti-CTLA4 immunotherapy, such
as found with ipilimumab, is able to target senescence of CD8+ cytotoxic and CD4+ T cell
populations. It does this by blocking the effect of CTLA4, a T cell inhibitory molecule similar
in function to costimulatory protein CD28, on the surface of the T lymphocyte that limits
clonal expansion (Riley 2013). As this therapy globally increases T cell numbers, serious
adverse side effects, such as autoimmunity, are directly linked to this function, by causing
over-activation of the immune system. Ipilimumab is currently being investigated for
potential treatment of other cancer types, while other immunotherapies targeting T cell
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response are also being tested for efficacy against melanoma and other cancer types to
improve efficacy and safety (Pardoll 2012).
Similar to the actions of CTLA-4, PD-1 is also an inhibitory protein expressed on
the surface of chronically activated T cells, which show decreased TCR-mediated
proliferative and cytokine-releasing ability. Its expression is increased, compared to
peripheral blood cells, on tumor-infiltrating T-lymphocytes (Mockler 2014, Ahmadezadeh
2009). PD-1, along with its ligand that is also upregulated in the tumor microenvironment,
PD-L1, is currently being investigated as a potential immunotherapy target in clinical trials.
An anti-PD-L1 antibody was administered to patients with melanoma, colorectal, renalcell, ovarian, pancreatic, gastric, breast, or non-small-cell lung cancers. Patients were
treated for an average of 12 weeks and evaluated. A durable tumor regression response
was recorded at 6%–17%, while 12%–41% of patients experienced prolonged disease
stabilization over a period of 24 weeks (Brahmer 2012). Drugs targeting PD-1 or PD-L1
seem to have a slightly better safety profile compared with anti-CTLA4 and may prove to
be more effective as combination therapies (Rech and Vonderheide 2013, Chen 2012).

4.3.1.4. Summarizing the Rise of Immunotherapies
Overall, immune system modulators, ACT therapies, and oncolytic viruses all show
promise clinically, but their considerable development and clinical costs, safety profiles,
and limited efficacy in certain patient populations are a substantial obstacle to a broad
clinical impact on patient response and management. However, these technologies and
molecular targets may not only be useful as therapeutics to treat patients in the clinic, but
can be used as preclinical tools to investigate and better define the interplay between
cancer and immunology systems for further pharmaceutical development. To ensure
these tools are used in a way that minimizes financial and patient risk in pharmaceutical
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development, it is necessary to use these tools in appropriate preclinical models for
investigation and success of future cancer immunotherapies. In the next section, the use
of appropriate system models that should be used with these potential preclinical and
clinical tools for cancer treatment will be discussed.

4.3.2. Modeling the System for Pharmaceutical Aims
Knowing the particular causal suppression mechanisms at work in a cancer from
observations of biological state is one of the most pervasive problems in the analysis of
physiological systems. In engineering, this problem is called an identification problem,
where causal relationships between system elements are inferred from a set of input cues
and output responses (Khoo 1999). In context of cancer, an input cue may be antibodies
against tumor-specific epitopes and an output response may be tumor regression. Many
approaches

exist

for

the

identification

of

simple-input-simple-output

(SISO)

systems―where a change in input causes a unique change in output.
As a consequence of reductionist methods, there is a wealth of experimental data
that characterize how isolated elements of physiological systems respond to inputs.
However, approaches for identifying causal relationships among elements of more
complex integrated closed-loop systems, like the immune system, are less well developed.
Typically, a closed-loop system is defined as a multi-element system where the output
(i.e., response) of one element provides the input (i.e., biochemical cue) to another
element. A schematic diagram of a closed-loop system comprised of two cell types is
shown in Figure 4.2. Closed-loop systems are particularly challenging as it is impossible
to identify the relationships among cells of a system based upon overall input (e.g., tumor
vaccines) and output (e.g., tumor regression) measurements. One of the reasons for this
is that changes in the internal state of the system may alter the response of the system to
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a defined input, such that there is not a direct causal relationship between overall system
input and output.

Figure 4.2. Closed-Loop versus Open-Loop Cellular Systems. Studying open-loop
cellular systems, as indicated by the red open-dash box, involves directly
examining at a target cell or a cell population, without regard to the other cells,
inputs, or outputs that may be affecting the behavior of that particular cell. Closedloop systems examine multiple components of the overall system, including cues
going into the system, interactions within the cellular environment, and outputs
resulting from the multiple dynamics of cellular signaling and communication.
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Historically, the causal mechanisms underlying the behavior of closed-loop
systems in physiology have been identified via ingenious methods for isolating elements
within the integrated system (i.e., “opening the loop”). A classic example of this is the
discovery of insulin and its role in connecting food intake to substrate metabolism. As
insulin is only produced by the endocrine pancreas, measuring plasma insulin provides a
direct measure of the organ-level communication between food intake and substrate
metabolism in the peripheral tissues. The pancreas can then be approximated as a SISO
system where the glucose concentration in the portal vein is the input and insulin release
into the plasma is the output, as depicted in the Minimal Model for the regulation of blood
glucose (Bergeman 1989). Measuring changes in insulin in the blood in response to
changes in plasma glucose provide the basis for partitioning alterations in system
response (e.g., diabetes) into deficiencies in insulin production (i.e., type 1 diabetes) and
insulin action (i.e., type 2 diabetes). Treatment for diabetes is tailored to the deficiency in
component function that exists in the patient. In diabetes, “opening the loop” means
identifying organ-level cross-talk using blood measurements. In contrast, the cell-level
cross-talk between tumor and immune cells occurs locally within the tumor
microenvironment and may not reach a titer sufficient enough to detect using blood
measurements.

4.3.2.1. Methods to Quantify and Characterize Cross-Talk: Developing Appropriate
Models
Because biological systems are dynamic and require inputs from a variety of
sources to maintain homeostasis, pathway cross-talk is essential for regulation of
equilibrium. Biologists have often depended on methods to quantify this cross-talk that
introduce scientific bias. Immunohistology, for example, requires the researcher to know
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what they are probing for. The same concern exists in Western blotting, classical reverse
transcriptase-polymerase chain reaction (RT-PCR), ELISAs, and flow cytometry, which
require labeling or probing for a specific molecular component. Because levels of gene
expression and proteins are dynamic in that they change with respect to both time and
response to a stimulus, it is difficult to say with certainty that a particular stimulus is direct
cause of protein expression or whether cross-talk between molecular pathways is involved
and causing an upregulation or downregulation of a particular gene and its translation into
protein gene product. This requires the researcher to have extensive knowledge of
“known” pathways and relies on previous data to support the hypothesis and conclusions.
Discovery-based research, using high-throughput methods to monitor expression
level changes in a wide variety of targets, was one way to combat this “known pathway”
requirement in cancer biomarker research. Discovery-based research, because it looks at
a variety of targets, which may or may not be known to have pathway association, may be
thought of as a way to combat methodological bias. However, in his Nature opinion paper
regarding biomarker research, Ransohoff argued target-driven discovery-based research
methods still portray a bias component, as “cancer group” samples may be handled in a
particular way or undergo particular procedures during collection and storage, whereas
“normal tissue” would not. In sensitive assays, which themselves may have these
molecular pathway biases, this can make data interpretation, statistical analyses, and
conclusions difficult and a technical bias may be inadvertently contributed to the protocol.
Ransohoff also discusses “fitting” of the model during biomarker research and how this
can become a bias in data analysis and conclusions (Ransohoff 2005). We expect certain
associations of molecules or patterns in signaling, and the researcher then tries to fit these
patterns to a certain disease. However, as protein and mRNA expression levels are highly
variable and individual samples or subjects can have divergent baselines, fitting the data
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to a certain model of gene or protein expression may not be a dependable method of
determining disease status conclusions.
One of the great challenges of biochemical research is that the biological activity
of many gene products are unknown, and therefore, it is unclear as to how they may
influence cellular response mechanisms. Proteomics workflow methods may remove
some of the bias of probing for known protein products. Studies conducted by our
laboratory on the secretomes of a “normal” breast epithelial line compared to the breast
cancer lines BT474 and SKBR3 provided a wealth of information on protein products that
may be selectively secreted by breast cancers. We performed this workflow by isolating
and enriching the secretomes from the cell lines, running the samples on a 2DE-gel and
using MALDI-TOF analysis to identify proteins secreted (Klinke 2014a). To gain insight
into common mechanisms for altering local intercellular communication in breast cancer,
we used computational tools to identify common pathway alterations an as a way to
counter uncertainty due to the inherent variability among samples and limits to sensitivity
of this experimental approach.
An alternative approach to identify alterations in intracellular communication is to
develop phenotypic screening assays. While the contemporary focus has largely been on
target-based drug discovery, phenotypic screening produced greater than 60% of first-inclass small molecule drugs approved by the FDA between 1999 and 2008 (Swinney and
Anthony 2011). Phenotypic screening assays are one method of discover-based research
that does not rely on target-based screening, as do many discovery-based research
methods, and is making a return to the field of pharmaceutical research (Kotz 2012).
Phenotypic screening assays rely on observing the effects of a particular stimulus on a
given outcome, rather than the players that may cause that outcome. It allows for some
uncertainty on what particular pathways are involved to effect disease status and can give
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insight to unknown molecular interactions and molecules acting via previously
undiscovered mechanisms. To illustrate the approach, we developed a phenotypic
screening assay to identify biochemical cues responsible for local immunosuppression in
vitro, validated these mechanisms in human tumor biopsy specimens, and correlated
these putative immunosuppressive mechanisms with clinical outcomes (Kulkarni 2012,
Klinke 2014b). The phenotypic screening assay also incorporated a mathematical model
that provides a quantitative prediction of a T cell response to Interleukin-12 in terms of
cytokine production and cell fate. As multiple factors were observed in the phenotypic
screening assay, the mathematical model provided a quantitative context to determine
whether the observed factors were sufficient to explain the observed changes in T cell
response or whether there were additional behaviors that were unexplained.

4.3.2.2. Computer Simulation Provides a Translational Bridge Across Model Systems
Even after defining signaling pathway components, it is still difficult for scientists
to predict the overall behavior of the system. Animal models are most commonly used to
predict the human response to a particular therapy and to replicate human systems.
However, success of therapeutic interventions seems to be more easily attained in
animals and brings to question the translational viability of animal models of disease (Wen
2012). As discussed previously, methodological bias may play a role in these
discrepancies. Moreover, humans are known to have fundamental differences in biology,
regardless of whether molecular components are conserved, and animal models are
usually made of clones of a particular population. Therefore, this does not account for the
heterogeneity of the human population, which will attribute different clinical responses.
Additionally, it is unclear how conserved cellular signaling networks across different model
systems. The heterogeneity of tumor cell populations and individual metabolic and disease
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state differences may further cloud this issue, even when “normal” human cellular
networks are well-defined.
Novel drug targets are often difficult to predict, due to the interplay of multiple
genes and systems and the differences between human and animal models. To overcome
these barriers to disease modeling, computer simulation using previous molecular
interaction and human clinical data may be able to elucidate these signaling network
differences (Sorger 2011, Coumans 2014). Quantitative systems pharmacology is now
being used to analyze drug interactions and provide insight to adverse effects, and has
been suggested as a method of selecting better drug candidates for development (Sorger
2011). Two recent studies highlight the different functions computer modeling may perform
in aiding in drug development.
In a study examining prostate cancer malignancies, human and mouse model data
was analyzed to determine master regulators of prostate cancer using the Algorithm for
the Reconstruction of Accurate Cellular Networks (ARACNe), which uses microarray data
to predict direct molecular interactions (Aytes 2014, Margolin 2006). A Master Regulator
Inference algorithm (MARINa) was then used to determine gene regulators of prostate
cancer. Co-expression of FOXM1 and CENPF was determined to promote prostate cancer
malignancy by synergistically acting via the PI3K and MAPK pathways. This suggests a
complicated feedback system that may be therapeutically difficult to target with current
treatments (Aytes 2014). Using this analysis could serve as a way to determine gene
interactions in tumor development and to help to better classify tumors based on their
phenotypes and genotypes.
Knowing gene regulators of malignancy could also be helpful in finding new targets
for therapy and determining adverse effects before they are observed in the clinic. In a
study regarding drug-induced peripheral neuropathy, data from DrugBank and
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Therapeutic Target Database was used to create pharmacological networks of peripheral
neuropathy-inducing drugs, their known targets, and the diseases for which they are used
to treat. The Database for Annotation, Visualization, and Integrated Discovery (DAVID)
was then used to identify connections between drug targets and cellular pathways.
Regulation of two genes, MYC and PAF15, were found to be correlated with a higher
incidence of drug-induced peripheral neuropathy and suggested drugs that may produce
this adverse effect, as well as targets for future studies to alleviate neuropathy symptoms
in the clinic (Hur 2014).

4.4 CONCLUSIONS
One of the most costly decisions a pharmaceutical company can make in regards
to a cancer immunotherapy is selecting the patient population to conduct the clinical trial.
Success of the drug is often determined by which patient populations the study is
conducted in. If an inappropriate cancer phenotype is selected for the study, adverse
events or inefficacy can stop the study and discourage the drug from continuing in the
development pipeline. Troubleshooting and optimizing the drug could prove more costly
than developing an entirely different drug. Most cell lines do not contain heterogeneous
populations of cancer cells, let alone T cells and other stromal cells, which can lead to
misleading results in preclinical trials for determining optimal cancer phenotypes.
Given validation of these computational methods, and by combining methods to
investigate both drug response and molecular signaling, we can begin to properly examine
cellular networks to infer on whether our biological experimental methods correctly
forecast patient outcomes and portray an accurate representation of biological activity of
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a certain therapy or whether that therapy is appropriate for use in a certain patient
population. Using computational tools to model relevant signaling networks and cancer
immunity may also remove some of the bias associated with sample processing and
inappropriate biological method selection. To improve the translational value of these
approaches, they should account for clonal evolution and heterogeneity of the system.
Combining system-targeting drugs with system modeling and phenotypic assays is in line
with NIH recommendations for more quantitative and systems pharmacology research,
and could prove to be our best resource in engaging host immunity in the fight against
cancer. Given our currently known limitations and the recent developments in cancer
immunotherapy research, the pharmaceutical industry can reinvigorate their model for
innovation with the help of quantitative and systems pharmacology techniques and
focusing on a systems perspective with respect to cancer.
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